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Background and Aims: Given gastrointestinal (GI) symptoms are a prominent extrapulmonary 
manifestation of COVID-19, we investigated intestinal infection with SARS-CoV-2, its effect on 
pathogenesis, and clinical significance.  
Methods: Human intestinal biopsy tissues were obtained from COVID-19 patients (n=19) and 
uninfected controls (n=10) for microscopic examination, CyTOF analyses and RNA sequencing. 
Additionally, disease severity and mortality were examined in patients with and without GI 
symptoms in two large, independent cohorts of hospitalized patients in the United States (n=634) 
and Europe (n=287) using multivariate logistic regressions.  
Results: COVID-19 cases and controls in the biopsy cohort were comparable for age, gender, 
rates of hospitalization and relevant comorbid conditions. SARS-CoV-2 was detected in small 
intestinal epithelial cells by immunofluorescence staining or electron microscopy, in 14 of 16 
patients studied. High dimensional analyses of GI tissues revealed low levels of inflammation, 
including downregulation of key inflammatory genes including IFNG, CXCL8, CXCL2 and IL1B 
and reduced frequencies of proinflammatory dendritic cells compared with controls. Consistent 
with these findings, we found a significant reduction n disease severity and mortality in patients 
presenting with GI symptoms that was independent of gender, age, and comorbid illnesses and 
despite similar nasopharyngeal SARS-CoV-2 viral loads. Furthermore, there was reduced levels 
of key inflammatory proteins in circulation in patients with GI symptoms. 
Conclusion: These data highlight the absence of a proinflammatory response in the GI tract 








presenting with GI symptoms was observed. A potential role of the GI tract in attenuating SARS-
CoV-2 associated inflammation needs to be further examined. 
Introduction 
Gastrointestinal (GI) symptoms comprising nausea, vomiting, and / or diarrhea1 are a common 
extrapulmonary manifestation in Coronavirus disease 2019 (COVID-19). Additionally, the 
presence of GI involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 
has also been suggested by clinical2, non-human primate3 and in vitro4, 5 data. However, to date, 
there is limited evidence of SARS-CoV-2 infection of human intestinal epithelial cells6 and there 
are no studies on the response of the GI immune syst m in COVID-19 patients.  
Given the immune dysregulation seen in COVID-197, 8, we aimed to document infection 
of the GI tract in patients with COVID-19, to define the cellular and transcriptomic changes 
within the GI tract, and to determine the impact of GI symptoms on COVID-19 outcomes. Here, 
we present findings from well-characterized cohorts of COVID-19 patients hospitalized in 
tertiary care centers, from both New York City, USA and Milan, Italy, where we conducted high 
dimensional analyses of mucosal and systemic immune parameters and investigated disease 
outcomes associated with GI involvement in COVID-19 patients.  
 
Materials and Methods 
Clinical cohorts 
1. Intestinal Biopsy Cohort 
Endoscopic biopsies were obtained from 20 COVID-19 and 10 control patients undergoing 
clinically indicated endoscopic procedures after informed consent with Mount Sinai Hospital 








and controls are provided in Supplementary Table 1 and 2. COVID-19 severity is defined in 
Supplementary Table 3 and Supplementary Methods. 
2. Discovery Cohort 
634 subjects with COVID-19, admitted to MSH between April 1, 2020 and April 15, 2020, who 
met study inclusion criteria were enrolled in a Discovery Cohort under an IRB approved protocol 
(IRB-20-03297A) (Supplementary Methods). 
3. External Validation Cohort 
We analyzed a cohort of 287 patients admitted to a tertiary care center in Milan, Italy between 
February 22, 2020 and March 30, 2020 with COVID-19 (Supplementary Methods).  
4. Internal Validation Cohort 
A distinct ‘Internal Validation Cohort’ of patients who were hospitalized at MSH between April 
16, 2020 and April 30, 2020 (Supplementary Methods) was analyzed using a predictive model.   
Immunofluorescent (IF) microscopy 
Formalin fixed, paraffin embedded tissue was analyzed (Supplementary Methods). Primary and 
secondary antibodies are summarized in Supplementary Table 16.  
Transmission Electron Microscopy (TEM) and Electron Tomography (ET) 
Biopsy specimens and infected Vero E6 cells (positive control) were examined by electron 
microscopy (Supplementary Methods).  
Cell Culture Experiments, Virus Isolation, and Viral RNA Detection from GI biopsy tissues 
Endoscopic biopsy tissue samples were homogenized, inoculated on Vero E6 monolayers under 
biosafety level 3 (BSL-3) conditions and monitored daily for potential cytopathic effect (CPE). 








assay (Supplementary Methods). To detect SARS-CoV-2 RNA from intestinal biopsies, a 
modified version of the CDC 2019-nCoV RT-qPCR was used (Supplementary Methods). 
Biopsy collection and processing for Mass cytometry (CyTOF) 
Endoscopic biopsies were processed in BSL-3 facility within 2 hours of collection to obtain 
suspension of the epithelial compartment (EC) and lamina propria (LP) (Supplementary 
Methods). 
CyTOF processing, data acquisition, and data analysis 
Cells were processed as previously described9, acquired on a Helios Mass Cytometer, and de-
multiplexed using the Zunder single cell debarcoder. De-barcoded files were uploaded to 
Cytobank for analyses, followed by annotation using Astrolabe Cytometry Platform (Astrolabe 
Diagnostics, Inc.) and clustering using Clustergrammer2's interactive heatmap (Supplementary 
Methods). 
Blood collection and processing for CyTOF 
Phlebotomy was performed on the Intestinal Biopsy Cohort patients at the time of endoscopic 
evaluation. Blood samples from COVID-19 patients were processed in enhanced BSL2 
conditions (Supplementary Methods).  
Specimen Processing for Nucleic Acid Extraction and RNA sequencing 
Total RNA was extracted from the cells isolated from both the intestinal compartments, EC and 
LP cellular fractions, using Direct-zol RNA Miniprep Plus (Zymo) kit according to the 
manufacturer’s instructions. RNA from cases and controls was then used for qRT-PCR and RNA 
sequencing (Supplementary Methods). 
RNA Sequencing 








RNA-sequencing (RNA-seq) was performed on RNA isolated from the EC and LP samples 
obtained from COVID-19 cases and controls (Supplementary Methods). 
Computational analyses 
Descriptive statistics 
For univariable statistical analyses, Graph Pad Prism (version 8) was used to calculate unpaired 
two tailed t-test for continuous variables and either Fisher’s exact test or the Chi-square test for 
categorical variables. 
Multivariate model based on Discovery Cohort and External Validation cohort 
A multivariate logistic regression was utilized to model each outcome as function of GI 
symptoms and clinical variables including age, gender, body mass index (BMI) and 
comorbidities. Significant associations were determined based on 95% confidence interval (CI) 
based on 1000 bootstrap iterations (Supplementary Methods). 
Predictive performance based on the Internal Validation Cohort 
Only age and BMI were adjusted for, since they were the only variables significantly associated 
with both outcomes across different GI symptoms models in the Discovery Cohort 
(Supplementary Table 9). Then, the estimated model was utilized to predict the outcome of 
patients in the Internal Validation Cohort.  
Average treatment effect (ATE) 
ATE of GI symptoms on COVID-19 outcomes was estimated via the TMLE (Target Maximum 
Likelihood Estimation) package available in R Cran10. 
Quantification of SARS-CoV-2 nasopharyngeal (NP) viral loads 
SARS-CoV-2 viral loads were determined as previously reported11 (Supplementary Methods).  








The ELLA cytokine platform measured TNF-α, IL-6, IL-8, and IL-1β8. Unpaired two-tailed t-
tests were used to compare individual cytokines quantified by the ELLA panel between GI 
symptomatic and asymptomatic groups. P-values were adjusted via Benjamini-Hochberg12. 
Multiplexed proteomic assay (Olink) 
Multiplexed proteomic inflammation panel (Olink, 92 inflammation-related proteins) was used 
to quantify circulating cytokines using an antibody-mediated proximity extension-based assay. 
The Benjamini-Hochberg procedure was used to adjust P values for multiple testing. 
Consensus Clustering of Olink Data and defining associations with GI symptoms 
Consensus clustering was performed on the abundance of the 92 cytokines across all 238 
samples using the R package ConsensusClusterPlus13. Associations between GI symptoms and 
Olink proteomic data were derived using unpaired t-tes  comparing the symptomatic and 




The gastrointestinal tract was endoscopically uninflamed in COVID-19 cases 
Twenty COVID-19 patients and 10 uninfected controls underwent 
esophagogastroduodenoscopy, colonoscopy or both (Supplementary Table 1 and 2). Patient 10 
was excluded after multiple negative SARS-CoV-2 NP PCR tests and negative COVID-19 
antibody test. COVID-19 cases and controls in the biopsy cohort were comparable for age, 
gender, rates of hospitalization and relevant comorbidities (Supplementary Table 1). Of the 
COVID-19 cases, 12 were classified as asymptomatic / mild / moderate and 7 as severe 








positive NP swab. Of the 19 patients, 12 (63%) had a positive SARS-COV-2 PCR swab most 
proximal to their biopsy while 7 (37%) had a negative swab (after previously being positive) 
(Figure 1A, Supplementary Table 2). COVID-19 treatment regimens and presence of GI 
symptoms are detailed in Supplementary Table 2. Sample allocation for different assays is 
detailed in Supplementary Table 2 and Supplementary Figure 1. 
The GI mucosa was endoscopically uninflamed in all subjects (Figure 1B), except for one 
case where inflammation was attributed to transplant rejection. Histology was normal in 7 of the 
17 cases examined, while the remaining (n=10) cases had a mild increase in intraepithelial 
lymphocytes (IEL) and / or a scant neutrophilic infiltration (Figure 1C and D, Supplementary 
Figure 2). CD3+CD8+ IELs and CD3+CD8- IELs were not significantly different in patients 
(n=12, 10 duodenum, 2 ileum) compared to controls (n=9, 5 duodenum, 4 ileum) 
(Supplementary Figure 3).  
 
Small bowel intestinal epithelial cells have robust expression of Angiotensin converting 
enzyme-2 (ACE2) and harbor SARS-CoV-2 antigens 
Robust expression of ACE2 was noted on the small intesti al brush border in both controls and 
COVID-19 patients (Figure 2, A to D). Additionally, we detected SARS-CoV-2 nucleocapsid 
protein in small intestinal epithelial cells of 10 of 11 COVID-19 patients tested (Figure 2, E to H 
and J to M, Supplementary Figure 4 and Supplementary T ble 4) indicative of virus infection in 
these cells. When present, the distribution of viral antigens was exclusively seen in the 
epithelium and was patchy in the upper small intestin  (duodenum; Figure 2, E to H), but 
diffuse in the lower small intestines (ileum; Figure 2, J to M). The presence of viral antigens on 
IF did not correlate with the presence of histologic abnormalities. To further define viral 








performed. Viral nucleocapsid primarily co-localized with MUC2 representing infected goblet 
cells (Figure 2, O to Q). There were a few cells poitive for the viral nucleocapsid protein but 
negative for MUC2 which tended to be located at the base of the crypts (Figure 2, P to Q). The 
more diffuse viral antigen staining in the ileum as compared to the duodenum is not explained by 
apparent differences in ACE-2 protein expression (Figure 2, A to D), however, may be explained 
by increased goblet cells in the ileum15 and this data appears to be consistent with organoid 
cultures4. As negative controls, 5 duodenal and 6 ileal biopsies from 10 patients collected prior to 
the pandemic (Supplementary Table 5) showed no evidence of viral antigens (Figure 2, I and N, 
Supplementary Figure 5).  
 
Ultrastructural analyses of GI tissues reveal viral particles in small intestinal epithelial cells 
Next, we performed TEM in 16 patients. Eight of these patients showed presence of 70-110 nm 
viral particles in the intestinal epithelial cells of the duodenum and/or ileum by TEM 
(Supplementary Table 4). Representative ET images (Figure 2, R to W) showed the presence of 
viral particles morphologically suggestive of SARS-CoV-2 in the duodenum (Figure 2, R, S, V) 
and the ileum (Figure 2, T, U, W), confirmed with Immuno-EM using mouse polyclonal 
antiserum against SARS-CoV-2 RB (Figure 2, X, Y). These particles in the exit vesicles of 
duodenal goblet cells (Figure 2, R, S, V) are consistent with the co-localization of MUC2 
staining using IF. 
 








We inoculated Vero E6 cells with the supernatants of homogenized intestinal tissues, but did not 
observe any apparent cytopathic effects or plaque formation after 7-days culture. In addition, cell 
culture supernatants did not reveal the presence of viral RNA by RT-qPCR. 
 
GI lamina propria dendritic cells are depleted in COVID-19 patients 
Next, we performed mass cytometry (CyTOF) based immunophenotypic analysis on GI tissue 
and peripheral blood from a subset of COVID-19 cases (GI tissue, n = 13; blood, n = 10) and 
controls (GI tissue, n = 9; blood, n = 9) (Supplementary Table 1 and 2, Supplementary Figure 1). 
Lamina propria (LP) and epithelial compartment (EC) were analyzed separately. Immune 
populations were clustered on the basis of cell-type s ecific markers for both the intestinal 
compartments (LP and EC) and blood (Figure 3, A, C and G, Supplementary Figure 8A and 9A, 
Data file 1). While the overall distribution of canonical immune cell subsets in the GI LP were 
comparable between patients and controls (Figure 3, A and B (left panel)), few immune 
populations showed differences as detailed below. No clear differences in the LP could be 
discerned based on severity (Figure 3B (right panel), Data file 2). 
In the LP, CD206+CD1c+ cDC2 (conventional DCs-0.4-fold decrease, p=0.01) and 
plasmacytoid DCs (pDCs) were reduced in COVID-19 cases (0.5 fold decrease, p=0.07) (Figure 
3, D and E), analogous to changes described in the blood16. Effector (PD-1+CD38+) CD4+ and 
CD8+ T cells (Figure 3F) as well as CD8+CD103+ T cells (tissue resident memory) 
(Supplementary Figure 7A) were increased in patients compared to controls (1.7-fold increase, 
p=0.06). In the EC, there was decrease in CD206+cDC2 (0.4-fold decrease, p=0.05) and an 








3H). Alterations in other immune populations in the LP and EC are shown in Supplementary 
Figure 7 and 8, respectively. 
Among PBMCs, effector (PD-1+CD38+) CD4+ and CD8+ T cells were significantly 
increased in patients (Figure 3I). Alterations in monocytes, TREG and IgG
+ plasma cells are 
shown in Supplementary Figure 9. Finally, a significant increase in activated (CD29+CD38+) 
CD4+ T cells was noted in PBMCs (Supplementary Figure 10A) and a non-significant increase 
of these activated T cells in the LP of patients compared to controls (Supplementary Figure 10B). 
Details of all immune population changes are provided in Data file S2. 
Altogether, intestinal tissues of COVID-19 patients showed altered distribution of 
immune cell subsets, most notable for reduced frequencies of CD206+CD1c+ cDC2 and pDCs 
and an increased frequency of effector T cells.       
 
GI lamina propria pro-inflammatory pathways are downregulated in COVID-19 patients 
Next, we performed RNA-Seq on the EC and LP in 13 COVID-19 patients and 8 controls. The 
EC and LP clustered separately on the basis of their top transcriptional signatures, demonstrating 
distinctness of the two compartments (Supplementary Figure 11, Data file 3). 1063 differentially 
expressed genes (DEG) were identified out of total 11419 genes detected (Figure 4A, Data file 
3). The majority of DEGs were detected in the LP (1061, false discovery rate17 ≤ 0.05), 
compared to 12 DEGs in the EC that largely overlapped with the LP (Figure 4A). Both LP and 
EC showed upregulation of genes involved in immunomodulation, including the anti-microbial 
peptide LCN2, and the metallothioneins MT1E, MT1F, MT1H, MT1M, MT1X, MT2A and 
TMEM107. In addition, heat shock proteins, HSPA1A and HASPA1B, were downregulated in 








several KEGG pathways that were depleted in patients compared to controls (Figure 4B) 
including pathways linked to TH17 cell differentiation and inflammatory bowel disea s (IBD) 
which are characterized by the depletion of RORA, IL4R, IFNG, IL18R1, IL1B, STAT4 and HLA-
DRA. Pathways linked to antigen processing, TH1 and TH2 cell differentiation, and MAPK 
signaling were significantly downregulated in the LP from patients. In contrast, genes associated 
with amino acid metabolism (NOS2, SMS, ALDH2, GOT2), mineral absorption (MT1G, MT2A, 
MT1E), and mucin biosynthesis (GALNT7, GALNT3, GALNT8) were significantly upregulated in 
patients compared to controls (Figure 4B).  
 We considered the possibility that the observed expression changes could imply 
alterations in relative cell type proportions (in addition to transcriptional alterations within cells). 
Therefore, we interrogated data derived from single-cell RNA-seq18 for enrichment of cell type-
specific gene expression signatures. Consistent with our CyTOF data (Figure 3 and Data files 1 
and 2), genes associated with DCs and eosinophils were reduced in patients compared to controls 
(Figure 4C). Additionally, signatures related to the size of endothelial cell and mast cell pools 
were reduced, while genes linked to goblet cells, proliferating epithelial cells, enteroendocrine 
cells and epithelial stem cells were increased, possibly reflecting the sequelae of intestinal 
epithelial infection by SARS-CoV-2 and subsequent rcovery (Figure 4C).  
 We probed myeloid gene signatures further, and found significant downregulation of 
genes associated with pDC (DAPK1, IRF7, ICAM1 and GM2A), activated DCs (TNFAIP2, 
CD86, CD83), cDC1 (RELB, IRF8 and HLA-DRA) and cDC2 (CLEC7A and CLEC10A). 
Additionally, LP genes associated with inflammatory DCs (monocyte-derived DCs, MoDCs) 








C5AR1, SPI1, CSF1R, AOAH, ABCA) were significantly reduced (Figure 4D), consistent with 
our CyTOF results.  
 Next, we looked at the average EC and LP expression of recently reported gene 
signatures linked to the antiviral response against SARS-CoV-2 from post-mortem lung tissue7, 
and human intestinal organoids5. Although we did not observe a substantial acute SAR -CoV-2 
response, there was significant upregulation of LCN2 in both EC and LP, and OAS and GBP3 in 
LP only. Notably, we observed a trend towards induction of antiviral response genes in the EC, 
where expression of canonical antiviral genes such as IFI44L, IFIT1, IFITM3, IFI44, IFI6 and 
OAS3 was increased (Figure 4E, top panel).  
Finally, using gene set enrichment analysis (GSEA), we rank ordered the EC DEGs 
according to effect size (logFC * -logPvalue) and tested for enrichment in the reported SARS-
CoV-2 infected organoid gene signatures5 (Supplementary Figure 12A). The genes upregulated 
in the EC of patients were significantly enriched in the SARS-COV-2 infected organoid gene 
datasets. Hallmark pathway enrichment analyses on this ranked EC gene list revealed that the top 
two processes associated with genes upregulated in EC were interferon alpha response 
(normalized enrichment score (NES) 1.91, FDR<0.005) and interferon gamma response 
(NES=1.8, FDR=0.005) (Supplementary Figure 12B), indicative of the host antiviral response 
against SARS-CoV-2 in the EC. 
 Projection of our RNA-seq dataset on SARS-CoV-2 infected human bronchial epithelial 
cells7 revealed that several inflammatory cytokines and chemokines such as IL-1β, IFN-γ, 
CCL24 and CXCL8 were downregulated in the intestine of COVID-19 patients (Figure 4E, 
bottom panel). The only chemokine significantly increased was CCL15 which is structurally 








4E, bottom panel). Key inflammatory genes including IFNG, IL1B, CXCR4, TNFSF14, CXCL2, 
CSF-1, CXCL8, IL18R1, NRP1 and IL18BP were downregulated in LP of patients compared to 
controls (Figure 4F).  
 Together, these data reveal a dynamic remodeling of GI tissues by SARS-CoV-2, notably 
with a significant downregulation of pathways associated with inflammation and antigen 
presentation in the LP with a concomitant activation of antiviral response signaling genes in the 
EC. 
 
Clinical impact of GI involvement during COVID-19: frequency of GI symptoms in a 
Discovery Cohort 
Given the observed downregulation of key inflammatory genes, we hypothesized that intestinal 
involvement in COVID-19 is associated with a milder isease course. We tested this hypothesis 
in a ‘Discovery Cohort’ consisting of 634 hospitalized COVID-19 patients at MSH meeting 
inclusion criteria (Supplementary Figure 13). Demographics (gender, age and race/ethnicity) and 
clinical variables including the presence of comorbidities and COVID-19 severity were analyzed 
(Supplementary Table 6). Next, we recorded the presence of GI symptoms (diarrhea, nausea, 
vomiting) present at the time of hospital admission, t  avoid iatrogenic confounders. 299 patients 
(47%) reported any of the GI symptoms (nausea, vomiting and/or diarrhea) with diarrhea being 
the most common (245 patients, 39%), followed by nause  (157 patients, 25%), and then 
vomiting (82 patients, 13%) (Supplementary Table 6).  
 
COVID-19 severity is significantly reduced in patients with GI symptoms when compared to 








Among the Discovery Cohort, 54 (9%) patients had mild disease, 361 (57%) moderate, 158 
(25%) severe and 61 (10%) had severe COVID-19 with end organ damage (EOD) 
(Supplementary Table 3 and 6). 110 patients were admitted to the ICU (17%) and 151 patients 
(24%) died by the end of data collection (Supplementary Table 6).  Patients presenting with GI 
symptoms had less severe disease than patients without GI symptoms (p<0.001 Chi-square test, 
Table 1). Notably, only 54 (9%) patients in the entir  cohort [31(10.3%) with and 23(6.8%) 
without GI symptoms respectively] had mild disease on presentation (i.e.  not requiring any type 
of supplemental oxygen (SpO2>94% on room air) and with no evidence of pneumonia), 
therefore, a majority of patients with GI symptoms had concomitant respiratory symptoms. 
Mortality was significantly lower in COVID-19 patients with GI symptoms (15.7%) than those 
without GI symptoms (31.0%; p<0.0001 Fisher’s exact test) (Table 1). Furthermore, each 
individual GI symptom (nausea, vomiting and diarrhea) was associated with less severe disease 
(p<0.02 Fisher’s exact test) and lower mortality (p<0.001 Fisher’s exact test) (Supplementary 
Table 7).  These findings were further emphasized by Kaplan-Meier estimates of survival over 
short-term follow-up of 25 days (p<0.001 log-rank test) (Figure 5A and Supplementary Figure 
14, A and B). Consistent with prior reports8 older age and higher disease severity were 
associated with higher mortality (Supplementary Table 8).  
Next, we created a multivariate model, adjusting for age, BMI, gender, race/ethnicity, 
diabetes, HTN, chronic lung disease and heart disease to determine the impact of GI symptoms 
on COVID-19 outcomes (Table 1). Consistent with published literature20 age and BMI were 
positively associated with COVID-19 severity and mortality (Supplementary Table 9). The 
presence of any GI symptoms, as well as diarrhea, nausea, and vomiting individually, were 








Patients who presented with GI symptoms had 50% reduced odds of having severe disease (odds 
ratio (OR) of 0.56) and death from COVID-19 (OR of 0.54), compared to the patients who 
presented without GI symptoms (Figure 5B, Supplementary Table 9).  
  
An External Validation Cohort further confirms decreased mortality in COVID-19 patients 
with GI symptoms on multivariate testing 
Next, we confirmed our findings in an External Valid tion Cohort in which GI symptoms on 
admission were characterized as presence or absence of diarrhea (Supplementary Table 10). 
Consistent with the Discovery Cohort, patients with diarrhea on admission had significantly 
lower mortality (10.0%) compared to patients without diarrhea (23.7%, p=0.008). Additionally, 
patients with diarrhea had lower composite outcome f mortality or ICU admission compared to 
those without diarrhea (20% vs 40%, p=0.001) (Supplementary Table 10). On multivariate 
logistic regression analyses, adjusting for age, gender, BMI, diabetes, chronic heart and lung 
disease and other confounders, we observed that the presence of diarrhea on admission was 
significantly inversely associated with mortality with a median OR of 0.33 over 1000 bootstrap 
iterations (Figure 5C). In 270 patients in which treatment data was available, no specific 
treatment was associated with GI symptoms (p-values > 0.05) (Supplementary Table 11). In 
addition, diarrhea was significantly associated with mortality after adjusting for all treatments 
(Supplementary Table 11). Thus, our observations from this External Validation Cohort were in 
alignment with those from the Discovery Cohort. 
 









Next, we developed a predictive model based on the Discovery Cohort and applied it to a distinct 
Internal Validation Cohort. The inclusion of ‘any GI symptoms’ to a model consisting of age and 
BMI, improved the ability to predict severity and mortality with a median area under the curve 
(AUC) of 0.64 (age + BMI + any GI symptoms) vs 0.59 (age + BMI) for disease severity and 
0.73 (age + BMI + any GI symptoms) vs 0.70 (age + BMI) for mortality (Figure 5D, 
Supplementary Table 12). In addition, the effect of GI symptoms, age and BMI on the AUC was 
evaluated by excluding each variable one at a time from the model and calculating the 
consequent reduction in AUC. The exclusion of GI symptoms resulted in a significant reduction 
in AUC with a median value of 0.054 for disease severity and 0.03 for mortality. Notably, the 
effect of GI symptoms on the AUC was more dramatic than that of age (AUC reduction of 0.054 
versus 0.025) for disease severity (Figure 5E, Supplementary Table 12). 
 
Average treatment effect (ATE) of GI symptoms on COVID-19 outcomes 
Using causal inference methodology, we quantified the ATE of GI symptoms on COVID-19 
outcomes while accounting for potential confounders. We performed this analysis on the MSH 
Cohort combining Discovery and Internal Validation Cohort and on the External Validation 
Cohort. The marginal effect of GI symptoms in the MSH cohort was significant for both severity 
and mortality after adjusting for all confounders (Data file 4). Additionally, based on the 
External Validation Cohort, the ATE for diarrhea was significant for mortality and combined 
outcome of ICU admission or death, but not for ICU admission alone (Data file 4). The OR for 










Nasopharyngeal SARS-CoV-2 viral loads are similar in patients with and without GI 
symptoms. 
Given recent reports suggesting that NP SARS-CoV-2 viral loads are correlated with disease 
outcomes11, we compared NP viral loads in a subset of Discovery and Internal Validation Cohort 
(n=329, where data available). Patients with and without GI symptoms had comparable SARS-
CoV-2 NP viral loads (mean log10 copies/mL 5.1 (SD 2.3) and 5.6 (SD 2.4), respectively) 
(p=0.07); furthermore, no significant differences were observed for each individual GI symptom 
(Figure 5F). 
 
COVID-19 patients with GI symptoms have reduced levels of circulating cytokines associated 
with inflammation and tissue damage. 
To correlate the observed mortality difference with GI symptoms with known biomarkers for 
severe COVID-19, we examined IL-6, IL-8, TNF-α, and IL-1β levels measured on admission. 
IL-6 and IL-8, which are known to be directly associated with poor survival8, were found to be 
significantly reduced in circulation of patients with GI symptoms (FDR 10%) (Supplementary 
Figure 15, Supplementary Table 13).   
Next, we performed a validated, multiplexed proteomic assay (Olink), in 238 patients 
(from among the Discovery and Internal Validation Cohorts; GI symptoms (n=104), no GI 
symptoms (n=134)) where serum samples were available for analyses. Unsupervised consensus 
clustering of 92 analytes revealed six groups of analytes with similar expression patterns across 
all patients (Figure 6A, Supplementary Table 14). Analytes in clusters 5 and 6 displayed less 
correlation in patients with GI symptoms compared to those without GI symptoms (Figure 6A, 
Supplementary Figure 16). “KEGG Jak/Stat Signaling Pathway” was significantly enriched in 








Cluster 4 (Fisher’s exact test 10% FDR). These pathw ys were downregulated in patients with 
diarrhea (p<0.05 from t-test) (Figure 6B), suggesting a reduced inflammatory response in 
patients with GI symptoms. Additionally, Clusters 1, 2, 3, 5 and 6 were significantly 
downregulated in patients with GI symptoms compared to those without (FDR 15%) (Figure 
6C). This seemed to be driven mostly by diarrhea since the same clusters were significantly 
downregulated in patients with diarrhea (FDR 10%). We observed a similar, albeit a reduced 
signal for nausea and vomiting likely due to the smaller sample size (n=29 for vomiting, n=54 
for nausea).  
Key inflammatory cytokines and chemokines were significantly downregulated (IL-8, 
TGF-α, IL-17C, IL-15RA, IL-10RB, MMP10, TNFRSF9, OPG, IL-6, LIF, GDNF, IL-17A, 
ARTN and CCL28) while TNF-Related Apoptosis Inducing Ligand (TRAIL), a cytokine with 
immune regulatory properties21 and IL-7, a cytokine associated with T cell development22 were 
significantly upregulated in patients with GI symptoms (t-test FDR 10%) (Figure 6, D and E, 
Supplementary Table 15).  
Overall, GI symptoms are associated with significantly reduced levels of key 
inflammatory cytokines including IL-6, IL-8, IL-17 and CCL28 that are known to be associated 
with poor COVID-19 outcomes.  
 
Discussion 
Given the robust expression of ACE2 on the small intestinal epithelium, we hypothesized 
that the intestines would be susceptible to SARS-CoV 2 infection. Here, we detailed for the first 
time SARS-CoV-2 infection of human intestinal epithelial cells in vivo using IF and EM. 








inflammatory response in the intestinal tissues despit  the presence of SARS-CoV-2 antigens. 
Finally, we found reduced systemic inflammation as well as mortality in hospitalized COVID-19 
patients presenting with GI symptoms.  
Using multiple approaches, we observed evidence of reduced inflammatory response 
within the GI tract. This includes a lack of inflammatory monocytes and macrophages and a 
depletion of DC subsets in the GI tract which is in contrast to the significant inflammatory 
response observed in the blood and lungs of severe COVID-19 patients23. Additionally, a 
downregulation of several proinflammatory genes that were found to be elevated in the lungs 
during SARS-CoV-2 infection24 was observed in GI tissues. Lastly, systemic levels of IL-6 and 
IL-8 as well as IL-1720 and CCL2825 were lower in hospitalized patients presenting with GI 
symptoms, despite comparable NP SARS-CoV-2 viral lods. Notably, the reduced circulating 
IL-17 and CCL28 (by Olink) is consistent with our RNAseq data. The observed attenuation of GI 
inflammation is in alignment with data from the 2003 SARS epidemic26, autopsy studies from 
COVID-19 patients27 and from animal models28, 29.  
In two distinct and large cohorts of COVID-19 patien s, we observed a significant 
reduction in mortality in patients presenting with GI symptoms compared to those without GI 
symptoms, even after adjusting for multiple confounders including age and comorbidities, which 
is consistent with findings in two smaller cohorts30, 31. Notably this finding is different from early 
reports suggesting increased severity with GI sympto s32, likely attributable to the inclusion of 
abnormal liver function tests which are associated with poor outcomes.  
We duly acknowledge some limitations of our study. GI biopsies were performed on a 
distinct set of patients undergoing clinically indicated procedures and therefore, they were not all 








symptoms, we were unable to perform comparisons between those with and without GI 
symptoms. Although we could not isolate infectious virus from intestinal biopsies (possibly due 
to culture methods, low multiplicity of infection or inactivation of virus following contact with 
enteric secretions) we demonstrate presence of virus in intestinal tissue using two parallel 
methods, IF and EM/ET. One of the possible reasons why SARS-CoV-2 induced less severe 
inflammation in the gut could be through the induction of potent neutralizing IgA antibodies 
which are predominantly produced in the intestines and do not fix complement unlike IgG 
antibodies mainly induced in the lungs33, 34. Furthermore, dimeric IgA (as would be induced in 
the gut) is more potent in viral neutralization than IgG35. Finally, we acknowledge that reporting 
of GI symptoms can be subject to individual variation and has the potential for being under 
reported.  
In summary, our data detail the previously unappreciat d GI tissue response to SARS-
CoV-2 and provide the rationale for future mechanistic studies to understand a possible 
attenuation of SARS-CoV-2 pathogenicity by the intestinal environment. 
 
Figures and Table Legends 
Figure 1 Clinical timing, endoscopic findings and histologic features in the small intestines 
of COVID-19 patients. (A) Timing of GI evaluation with respect to COVID-19 disease course. 
(B) Representative endoscopic images of the duodenum i  COVID-19 (left) and control (right) 
patients. (C) Histologically normal duodenal tissue in a COVID-19 patient. (D) Histologic signs 
of inflammation detected in duodenal biopsies of COVID-19 patients including neutrophils 









Figure 2 SARS-CoV-2 viral particles and protein are detectable in intestinal tissues of 
COVID-19 patients. (A-H) Immunofluorescence (IF) staining of duodenal (A, B) and ileal (C, 
D) biopsies of COVID-19 patients (B, D) and controls (A, C) with ACE2 (green), EPCAM (red) 
and DAPI (blue). (E-N) IF staining of duodenal (E-I ) and ileal (J-N) biopsies from patients (E-
H, J-M ) and controls (I, N) with SARS-CoV-2 nucleocapsid (green), EPCAM (red) and DAPI 
(blue) including isotype (G, L) and no primary (H, M ) controls. (O-Q) IF staining of duodenal 
(O, P) and ileal (Q) biopsies of patients with SARS-CoV-2 nucleocapsid (green), MUC2 (red) 
and DAPI (blue) showing SARS-CoV-2 nucleocapsid in goblet cells (*, MUC2+) and non-goblet 
epithelial cells (arrows, MUC2-). (R-W) Electron tomography (ET) of a duodenal biopsy (R,
montaged projection overview; S, Tomographic reconstruction of the region indicated by the 
rectangle in R showing the goblet cell Golgi region; V, Detail of the presumptive virion 
indicated by the red arrow in S. Note dark nucleocapsid puncta and surface spikes (arrows). ET 
of an ileal biopsy from a COVID-19 patient (T), montaged tomographic reconstruction of a 
goblet cell Golgi region; U, Detail of the region indicated by the rectangle in T, showing a 
presumptive exit compartment containing 5 presumptive SARS-CoV-2 virions; W, Detail of a 
presumptive virion from U, membrane bilayer and surface spikes are evident. The virion 
structures in R-W are comparable with those from a SARS-CoV-2–infected cultured cell 
(Supplementary Figure 6 and Supplementary Movies 1-2). Projection image (X) of a 
presumptive SARS-CoV-2 virion within an intestinal epithelial cell of CGI-115, labeled with a 
mouse polyclonal antiserum against SARS-CoV-2 RBD36 and 10 nm gold conjugated anti-mouse 
secondary antibodies. Detail of the presumptive virion itself is not apparent in the projection 
image. A single slice (Y) (~10 nm) from a tomographic reconstruction of the same area shown in 








are discernible, with gold particles connoting anti-S labeling localized to the presumptive 
virion’s outer periphery. Scale bars; 100 µm (A-N), 10 µm (O-Q), 5 µm (R), 0.2 µm (S, U), 1 
µm (T), 0.05 µm (V, W), 0.025 µm (X,Y). 
 
Figure 3 CyTOF-based analysis identified immune cell signatures in intestinal biopsies and 
blood from COVID-19 patients and controls. Uniform Manifold Approximation and 
Projection (UMAP) presentation of the eight cluster of LP immune populations based on 38 
markers (A), by infection status (B, left panel) with COVID-19 patients (red) and contr ls (blue), 
and by disease severity (B, right panel) with controls (blue), severe (red) and 
asymptomatic/mild/moderate (green) COVID-19 patients. (C) The heatmap depicting immune 
populations in the LP based on specific cell type markers. (D) Representative histograms 
comparing CD206+ and CD123+ in DC subsets in patients (red) and controls (blue). (E) Relative 
frequencies of CD206+ cDC2 and plasmacytoid DCs in LP of patients and controls 
(unsupervised analysis). (F) Relative frequencies of PD-1+ CD38+ (effector) CD4+ and CD8+ T 
cells in LP of control and patients (supervised analysis). (G) UMAP presentation of the eight 
clusters of immune populations based on 38 markers in the EC of intestinal biopsies. (H) 
Relative frequencies of CD206+ cDC2 and CD4-CD8- T cells in the EC of controls and patients 
(unsupervised analysis). (I ) Relative frequencies of PD-1+CD38+ (effector) CD4+ and CD8+ T 
cells in blood of controls and patients (supervised analysis). Open red circles denote patients 
with asymptomatic/mild/moderate disease while filled red circles denote patients with severe 









Figure 4 Transcriptional changes in intestinal biopsies from COVID-19 patients compared 
with controls. (A) Hierarchical clustering of average expression changes for 1,063 genes (rows) 
with induced (red) or depleted (blue) expression (FDR ≤ 0.05) in the EC and LP of intestinal 
biopsies from COVID-19 patients. The panel on the left indicates significant genes for each 
tissue fraction in yellow. The color bar indicates the average log2 fold-change (FC). (B) Top 
enriched pathways (KEGG) that are induced (red) or depleted (blue) in LP of COVID-19 patients 
are displayed. The dash line indicates the P ≤ .05 cutoff. Gene names are indicated for main 
pathways.   (C) Deconvolution of main gastrointestinal cell types enriched or depleted in the LP 
of COVID-19 patients compared with controls. Reference scRNA-seq cell type signatures were 
taken from Smillie et al. 2019. (P ≤ .05, Fisher’s exact test). (D) Average expression changes for 
dendritic cell markers in the EC and LP. Reference s RNA-seq cell type signatures were taken 
from Martin et al. 2019. The color bar indicates the average log2 FC. (E) Hierarchical clustering 
of average expression changes (columns) in the EC and LP for genes related to antiviral response 
to SARS-CoV-2 in post-mortem lung tissue of COVID-19 patients as described by Blanco-Mello 
et al. 2020 (top panel) and for cytokines and chemokines (bottom panel). The color bar indicates 
the average log2 FC. (F) The gene expression levels for the top 10 significant hemokines and 
cytokines in the LP of COVID-19 patients and controls. * P < .05, ** P < .01. 
 
Figure 5 COVID-19 patients with GI symptoms had reduced severity and mortality despite 
similar nasopharyngeal viral loads compared to those without GI symptoms.  (A) Kaplan-
Meier (KM) curves for survival stratified by any GI Symptoms (left panel) and diarrhea (right 
panel) for patients in the Discovery Cohort. P-values from log-rank test and 95% confidence 








timepoints. (B) Confidence intervals (CI) of odds ratio (95%) of GIsymptoms based on 1000 
bootstrap iterations in a multivariate logistic regr ssion for severity (blue) and mortality (red). 
(C) Validation based on the External Cohort. CI of odds ratio (95%) of diarrhea covariate based 
on 1000 bootstrap iterations to capture mortality, ICU admission and composite outcome of ICU 
admission or death. Results are based on multivariate models after accounting for confounders 
including BMI, age, gender, lung disease, heart disease and hypertension. (D) Validation based 
on the Internal Cohort. Boxplot of AUC over 1000 bootstrap iterations to predict mortality and 
disease severity in the Internal Validation Cohort. (E) CI of the reduction in AUC (95%) based 
on 1000 bootstrap iterations for the model “Age + BMI + Any GI Symptoms” after removing 
age (blue), GI symptoms (red) and BMI (green). (F) SARS-CoV-2 viral load copies per mL 
(log10 transformed based on N2 primer with the addition of a constant) stratified by GI 
symptoms. The square corresponds to the average viral load and the error bars show one standard 
deviation of uncertainty from the mean. P-values from two-tailed unpaired t-tests are reported. 
 
Figure 6 COVID-19 patients with GI symptoms have reduced levels of circulating 
inflammatory cytokines. (A) Correlation matrix (Pearson’s) for 92 markers in the Olink panel 
across patients with any GI symptoms (top left panel) compared with no GI symptoms (top right 
panel) and patients with diarrhea (bottom left panel) compared with patients without diarrhea 
(bottom right panel). Cluster assignment is reported on the top of the heatmap. (B) Boxplot of 
“Hallmark Inflammatory Response” and “KEGG JAK/STAT Signaling pathway” z-scores 
stratified by GI symptoms which were significantly enriched at 10% FDR in Cluster 4 and 
Cluster 5, respectively. (C) Significant associations between proteomic clusters and GI 








Analytes associated with GI symptoms at 10% FDR based on unpaired t-test. The intensity of the 
color is proportional to the -log10 p-value. Negative associations are in blue, while positive 
associations in red. On the right side of the heatmap, the cluster assignment for each marker is 
reported. (E) Boxplots represent median and interquartile range of select differentially expressed 
markers stratified by GI symptoms. P-values from unpaired t-test are reported. 
 
Table 1 Basic demographics, clinical characteristics and outcomes in patients with and 
without GI symptoms. For age, the mean ± standard deviation is listed and an unpaired two-
tailed t-test was performed. For categorical variables, the number of patients followed by the 
percent of patients in parentheses is listed and the Fisher’s exact test or the Chi-square test was 
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Table 1 Basic demographics, clinical characteristics and outcomes in patients with and 
without GI symptoms. For age, the mean ± standard deviation is listed and an unpaired two-
tailed t-test was performed. For categorical variables, the number of patients followed by the 
percent of patients in parentheses is listed and the Fisher’s exact test or the Chi-square test was 




No GI symptoms 
(n=335) P-value 
Age (years) 60.5 ± 15.0 67.2 ± 15.7 <.0001 
Male 168 (56.2) 201 (60.0) .33 
Race/ethnicities 
Hispanic 85 (28.4) 92 (27.5) 
.13 
African-American 66 (22.1) 95 (28.4) 
White 70 (23.4) 67 (20.0) 
Asian 22 (7.4) 13 (3.9) 
Other 56 (18.7) 68 (20.3) 
Comorbidities 
HTN 112 (37.5) 117 (34.9) .51 
Diabetes 58 (19.4) 83 (24.8) .13 
Obesity (BMI>30)* 108 (40.6) 103 (34.1) .12 
Chronic lung disease  34 (11.4) 25 (7.5) .10 
Heart disease 48 (16.1) 63 (18.8) .40 
Chronic kidney disease 41 (13.7) 54 (16.1) .44 
Cancer 27 (9.0) 39 (11.6) .30 
HIV 5 (1.7) 6 (1.8) .99 
IBD 4 (1.3) 3 (0.9) .71 
    
Disease severity    
Mild  31 (10.4) 23 (6.9)   
Moderate 188 (62.9) 173 (51.6)   
Severe 63 (21.1) 95 (28.4)   
Severe with EOD 17 (5.7) 44 (13.1) .0004 
    
Outcomes    
ICU admission 45 (15.1) 65 (19.4) .17 















Short summary: Intestinal infection with SARS-CoV-2 is associated with a mild inflammatory 
response and improved clinical outcomes. 
What you need to know 
BACKGROUND AND CONTEXT 
Gastrointestinal manifestations are common in COVID-19, however to date, there is limited 
evidence of SARS-CoV-2 infection of human enterocytes, tissue immune responses and 
relationship to clinical outcomes. 
NEW FINDINGS 
Immunofluorescence and electron microscopic detection of SARS-CoV-2 in small intestinal 
biopsies obtained from patients with COVID-19. 
Downregulation of key inflammatory pathways and reduced myeloid cells in intestinal biopsies. 
Lower severity and mortality in COVID-19 patients with GI symptoms in a multivariable model 
in 2 large independent cohorts from the United States nd Europe.  
LIMITATIONS 
Clinical documentation of GI symptoms might vary depending on providers and on the acuity of 
the patients’ presentation. 
IMPACT 
These data demonstrate in vivo GI tract infection by SARS-CoV-2 and the clinical impact of GI 










Intestinal host response to SARS-CoV-2 infection and COVID-19
outcomes in patients with gastrointestinal symptoms 
Supplementary materials and methods
Clinical cohorts
1. Intestinal Biopsy Cohort
Subjects included hospitalized patients at Mount Sinai Hospital (MSH) as well as those seen in
the outpatient GI practices that underwent endoscopy between April 17, 2020 and June 2, 2020.
COVID-19 cases and controls were defined on the basis of nasopharyngeal SARS-CoV-2 swab
PCR tests. Inclusion criteria included: (1) A positive nasopharyngeal (NP) SARS-CoV-2 PCR
test, relevant clinical symptoms and serological evidence of anti-SARS-CoV-2 antibodies (for
cases), and a negative NP SARS-CoV-2 test AND absence of fever, cough, shortness of breath
and relevant contact history (for controls); (2) Clinical indication for endoscopic procedure; and
(3) The patient and/or his/her health care proxy’s ability to provide informed consent. Exclusion
criteria  included:  (1)  Comorbid  conditions  including  severe  coagulopathy;  (2)  concomitant
anticoagulation use; (3) critical illness and any other clinical parameter which could potentially
increase the of risk of additional research biopsies; and (4) Failure to obtain consent. COVID-19
severity was defined based on internal scoring system developed by the Department of Infectious
Diseases at MSH. This scoring system was developed according to the  WHO Ordinal Clinical
Progression/Improvement  Scale  (https://www.who.int/publications/i/item/covid-19-therapeutic-
trial-synopsis)  and  based  on  oxygenation  status  and  organ  damage,  with  the  following
definitions:  Mild  -  SpO2>94%  on  room  air  AND  no  pneumonia  on  imaging,  Moderate  -
SpO2<94% on room air OR pneumonia on imaging, Severe - high flow nasal cannula (HFNC),
non-rebreather mask (NRBM), Bilevel Positive Airway Pressure (non-invasive positive airway
 
ventilation), or Mechanical ventilation AND no pressor medications AND creatinine clearance >
30 AND ALT < 5x upper limit of normal, Severe with evidence of end organ damage (EOD) -
high flow nasal canula (HFNC), non-rebreather mask (NRBM), Bilevel Positive Airway Pressure
(non-invasive positive airway ventilation), or Mechanical ventilation AND pressor medications
OR creatinine clearance <30 OR new renal replacement therapy OR ALT > 5x upper limit of
normal (Supplementary Table 3).
2. Discovery Cohort
Patients admitted to MSH between April  1, 2020 and April 15, 2020 were recruited into the
Discovery Cohort if they were SARS-CoV-2 PCR positive, more than 18 years of age and if the
“ELLA panel of cytokines” (IL-6, IL-8, IL-1 and TNF- was performed as part of clinical
care. Clinical details from eligible patients were extracted from Mount Sinai Data Warehouse
(MSDW) under  an  IRB approved protocol  (IRB-20-03297A North American  registry  of  the
digestive manifestations of COVID-19). Inclusion criteria included (1) A positive NP SARS-
CoV-2 PCR test within the Mount Sinai Health System between April 1-15, 2020 and admission
to the Mount Sinai Hospital;  (2) Age >18 years of age; and (3) Patients who had an ELLA
cytokine panel performed during hospitalization. Exclusion criteria included (1) Testing at a site
outside  of  Mount  Sinai  Hospital  in  an  ambulatory  setting  or  those  who  were  tested  in  the
emergency room but not admitted; (2) Patients <18 years of age; and (3) Patient’s without an
ELLA cytokine panel.
A total of 634 subjects were included in the Discovery Cohort (Supplementary Figure 11). In
addition  to  demographic  information  (including  race and ethnicity,  age  and gender),  clinical
characteristics, laboratory data and outcomes data was extracted from the medical charts. Co-
 
variates that were studied included: BMI (obesity defined as BMI >30) and comorbid conditions
including,  hypertension,  diabetes,  chronic  lung disease  (including  asthma and COPD),  heart
disease (including coronary artery disease, atrial fibrillation and heart failure), chronic kidney
disease, cancer, HIV, and inflammatory bowel disease (IBD). 
GI  symptoms were  defined  as  more  than  one  episode  of  either  diarrhea,  nausea,  and/or
vomiting at the time of admission. If only one episode of either diarrhea, nausea, and/or vomiting
was specifically documented, patients were not considered to have GI symptoms. Additionally,
we did not consider GI symptoms that developed during the course of hospitalization, as they
could reflect nosocomial or treatment-related effects and only considered the GI symptoms that
were present at the time of hospital admission so as to avoid including iatrogenic confounders
(treatments or hospital acquired illnesses that can result in diarrhea, nausea and vomiting).
Disease severity (as described above) and mortality were considered as outcomes variables.
Mortality  was  calculated  as  patient  status  (dead  or  alive)  at  25  days  post  admission.  If  no
information  was  available  after  discharge,  patients  were  censored  at  the  time  of  hospital
discharge. 
3. External Validation Cohort
This cohort consisted of 287 patients admitted to a tertiary care center in Milan, Italy between
February 22, 2020 and March 30, 2020, with a confirmed positive SARS-CoV-2 PCR and who
did not die or were not transferred to the ICU within 24 hours from admission were studied as
detailed in  Aghemo et al1.  Presence of vomiting and diarrhea (defined as at least three loose
bowel movement per day) on or prior to admission was recorded. Outcomes were analyzed using
ICU admission, death or the composite study end-point of ICU admission or death within 20
days of hospitalization. 
 
4. Internal Validation Cohort
The Internal Validation Cohort is a distinct cohort of patients admitted to MSH between April
16,  2020  and  April  30,  2020  used  to  test  a  predictive  model  for  COVID-19  severity  and
mortality. The same inclusion and exclusion criteria as in the Discovery Cohort were used with
the following differences: (1) A positive SARS-CoV-2 PCR test between April 16, 2020 and
April  30,  2020;  (2)  An  additional  exclusion  of  patients  that  were  already  included  in  the
Discovery Cohort. From a total of 408 patients, 242 met inclusion criteria and were thus included
in the Internal Validation Cohort. Demographic, clinical and outcomes related data was extracted
from patients’ medical records as described for the Discovery Cohort.
SARS-CoV-2 testing
The SARS-CoV-2 PCR was run in the Clinical Microbiology laboratory as part of routine care
on the Roche cobas platform which performs selective amplification of 2 targets ORF-1 gene
(Target  1) and the E-gene for pan-Sarbecovirus (Target  2) (detects  SARS-CoV-2 as well  as
SARS or MERS viruses, but not routine seasonal Coronavirus). A positive result indicated that
either  both  Target  1  and Target  2  were  detected  (majority  of  cases)  or  Target  1  alone  was
detected. A presumptive positive result indicates a negative Target 1 result and a positive Target
2 result which according to the manufacture can be a result of the following: “1) a sample at
concentrations near or below the limit of detection of the test, 2) a mutation in the Target 1 target
region in the oligo binding sites, or 3) infection with some other Sarbecovirus (e.g., SARS-CoV
or some other Sarbecovirus previously unknown to infect humans), or 4) other factors.” Patients
with a presumptive positive SARS-CoV-2 PCR were included in the analysis if they were treated
clinically as having COVID-19.
 
Immunofluorescent (IF) microscopy
Sections  (5µm)  of  formalin  fixed,  paraffin  embedded  tissue  were  dewaxed  in  xylene  and
rehydrated in graded alcohol and then washed in phosphate-buffered saline (PBS). Heat-induced
epitope retrieval was performed by incubating slides in a pressure cooker for 15 minutes on high
in target retrieval solution (Dako, S1699). Once slides cooled to room temperature, they were
washed twice in PBS and then permeabilized for 30 minutes in 0.1% tritonX-100 in PBS. Non-
specific binding was blocked with 10% goat serum for 1 hour at room temperature. Sections
were then incubated in primary antibodies diluted in blocking solution overnight at 4C. Primary
and secondary antibodies are summarized in  Supplementary Table 16. Slides were washed in
PBST  (0.1%  tween  20,  PBS)  thrice  and  then  incubated  in  secondary  antibody  and  4′,6-
diamidino-2-phenylindole (1g/mL) for 1 hour at room temperature. Sections were washed twice
in PBST and once in PBS then mounted with Fluoromount-G (Electron microscopy sciences,
1798425). Controls included,  omitting primary antibody (no primary control),  or substituting
primary antibodies with non-reactive antibodies of the same isotype (isotype control). Tissue was
visualized and imaged using a Nikon Eclipse Ni microscope and digital SLR camera (Nikon,
DS-Qi2). 
IEL quantification
Three-10x  non-overlapping  IF  images  were  taken  for  each  biopsy.  Twelve  biopsies  (10
duodenum, 2 ileum) from 11 COVID-19 patients in the biopsy cohort were analyzed along with
9  uninfected  controls  (5  duodenum,  4  ileum).  CD3+ intraepithelial  lymphocytes  (IELs)  and
CD3+ CD8+ (IELs) were quantified for each image. The length of epithelium in each image was
measured  in  ImageJ2.  Biopsies  from  COVID-19  patients  and  controls  were  compared  via
unpaired t test.
 
Routine Clinical Electron Microscopy (EM) 
Following post-fixation in 1% osmium tetroxide, tissues were serially dehydrated and embedded
in epoxy resin in standard fashion. One-micron toluidine-stained scout sections were prepared
for light  microscopic  orientation;  80 nm ultrathin  sections  for EM were stained with uranyl
acetate  and lead citrate and examined in a Hitachi 7650 transmission electron microscope at
80kV.
Infection of cultured cells for EM and Electron Tomography (ET) analyses
Viral infections of cultured cells were conducted at the UVM BSL-3 facility under an approved
Institutional Biosafety protocol. SARS-CoV-2 strain 2019-nCoV/USA_USA-WA1/2020 (WA1)
was  generously  provided by Kenneth  Plante  and the  World  Reference  Center  for  Emerging
Viruses and Arboviruses at the University of Texas Medical Branch and propagated in African
green monkey kidney cells (Vero E6) that were kindly provided by J.L Whitton. Vero E6 cells
were maintained in complete  Dulbecco's  Modified Eagle Medium (cDMEM; Thermo Fisher,
Cat. #11965–092) containing 10% fetal bovine serum (Gibco, Thermo-Fisher, Cat. #16140–071),
1% HEPES Buffer Solution (15630–130), and 1% penicillin–streptomycin (Thermo Fisher, Cat.
#15140–122). Cells were grown in a humidified incubator at 37ºC with 5% CO2. Vero E6 cells
seeded in six well dishes and infected with SARS-CoV-2 at a multiplicity of infection of 0.01 for
48 hours before fixing and preparing for electron microscopy. Cells  were pre-fixed with 3%
glutaraldehyde,  1%  paraformaldehyde,  5%  sucrose  in  0.1M  sodium  cacodylate  trihydrate,
 
removed from the plates and further prepared by high-pressure freezing and freeze-substitution
as described below.
Electron Microscopy and Dual-Axis Tomography of Intestinal Biopsy Tissue
Tissue samples were fixed with 3% glutaraldehyde to meet biosafety requirements. Tissues were
rinsed with cold 0.1M sodium cacodylate trihydrate + 5% sucrose and further dissected to block
sizes  sufficient  for  high-pressure  freezing.  Tissues  or  cultured  cells  were  rinsed  with  0.1M
cacodylate buffer containing 10% Ficoll (external cryoprotectant), placed into brass planchettes
(Ted Pella, Inc.) and ultra-rapidly frozen with a HPM-010 High Pressure Freezing Machine (Bal-
Tec/ABRA, Switzerland). Vitreously frozen samples were transferred under liquid nitrogen to
Nalgene cryogenic vials (Thermo-Fisher Scientific)  containing a frozen mixture of 2% OsO4,
0.05% uranyl  acetate  in  acetone.  Vials  were placed in  a  AFS-2 Freeze-substitution  machine
(Leica Microsystems, Vienna) and the samples freeze-substituted for 72 h at -90°C. Samples
were then warmed to -20°C over 24 h and held at that temperature for a further 12 h before being
warmed to room temperature, rinsed 3x with acetone, then infiltrated into Epon-Araldite resin
(Electron Microscopy Sciences). Samples were flat-embedded between two Teflon-coated glass
microscope slides and the resin polymerized at 60 °C for 24 h. Embedded tissue blocks were
observed by light microscopy to ascertain preservation quality and select regions of interest (i.e.,
apical epithelium). Blocks were extracted with a scalpel and glued to plastic sectioning stubs
prior to sectioning.  Semi-thin (150 nm) serial  sections were cut  with a UC6 ultramicrotome
(Leica Microsystems) using a diamond knife (Diatome, Ltd. Switzerland). Sections were placed
on formvar-coated copper-rhodium slot grids (Electron Microscopy Sciences) and stained with
3% uranyl acetate and lead citrate. Colloidal gold particles (10 nm) were placed on both surfaces
 
of the grids to serve as fiducial markers for tomographic image alignment. Grids were placed in a
dual-axis tomography holder (Model 2010, E.A. Fischione Instruments, Export PA) and imaged
with a Tecnai G2 T12 transmission electron microscope (120 KeV; ThermoFisher Scientific).
Images  were  recorded  with  a  2k  x  2k  CCD  camera  (XP1000;  Gatan,  Pleasonton,  CA).
Tomographic tilt series and large-area montages were acquired automatically using the SerialEM
software package3. For dual-axis tomography, images were collected at 1° intervals as samples
were tilted +/- 62°. The grid was then rotated 90° and a second tilt-series was acquired about the
orthogonal axis. Tomograms were calculated, analyzed and modeled using the IMOD software
package4, 5 on MacPro and iMac Pro computers (Apple, Inc). 
Presumptive SARS-CoV-2 virions were identified from tomographic reconstructions of
tissue samples by observing structures resembling virions described in cryo-electron tomography
studies  of  purified  SARS-CoV-2  and  SARS-CoV-2  in  infected  cells6-9 and  comparing  to
identified  virions within SARS-CoV-2–infected  cultured  cells  (Supplementary  Figure 6).  We
used the following criteria for SARS-CoV-2 virion identification in tissues: (i) Structures that
were  spherical  in  3D  and  not  continuous  with  other  adjacent  structures  with  ~60-120  nM
diameters, (ii) Spherical structures with densities corresponding to a distinct membrane bilayer,
internal puncta consistent with ribonucleoproteins6, and densities corresponding to surface spikes
on the external peripheries of the spheres. Particles resembling virions were examined in 3D by
tomography  prior  to  assignments  (Supplementary  Movies  1  and  2).  We note  that  the  inner
vesicles of multivesicular bodies (MVBs) have been mis-identified as SARS-CoV-2 by electron
microscopy10.  We therefore compared measurements of MVB inner vesicles and presumptive
coronavirus virions from what we identified as intracellular exit compartments within the same
tomogram (unpublished results) with our previous tomographic reconstructions of MVBs11,  12.
 
We distinguished virions inside a cytoplasmic exit compartment from the inner vesicles of an
MVB based on differences in size (MVB inner virions are generally smaller in diameter than
coronaviruses) and the presence of surface spikes and internal puncta (MVB inner vesicles do
not present surface spikes or internal puncta).
Cell Culture Experiments and Virus Isolation 
African  green  monkey  kidney  epithelial  cells  (Vero  E6)  were originally  purchased  from
American  Type  Culture  Collection  (ATCC).  Cells  were maintained  in  Dulbecco's  modified
Eagle's medium (DMEM) w/ L-glutamate, sodium pyruvate (Corning) supplemented with 10%
fetal  bovine  serum  (FBS),  100  U  penicillin/ml,  and  100  mg  streptomycin/ml.  For  all
experiments, the cells were always maintained in monolayers. 
Several  attempts  were  made  to  isolate  live  infectious  particles  from  these  biopsies.
Briefly,  biopsies  were  collected  and  stored  in  PBS  until  homogenization. Following
homogenization and centrifugation (10,000 × g, 20 min, 4°C), the resulting supernatant tissue
supernatant was inoculated onto Vero E6 monolayer maintained in optimal virus growth media
for  SARS-CoV-2  virus  (DMEM  w/  L-Glutamate,  Sodium  Pyruvate,  2%  FBS,  100  U
Penicillin/ml, and 100 mg Streptomycin/ml, 10 mM Non-Essential Amino Acids, 1 mM Sodium
Pyruvate and 10 mM HEPES). Vero E6 cells were incubated at 37 °C, 5% CO2 for a week and
monitored daily for potential cytopathic effect (CPE).
Cell culture supernatants were also collected and assessed for the presence of infective
particles by plaque assay. Briefly, ten-fold serial dilutions were performed in infection media for
SARS-CoV-2 and inoculated onto confluent Vero E6 cell monolayer in 6-well plate. After one-
hour adsorption, supernatants were removed, and cells monolayers were overlaid with minimum
 
essential media (MEM) containing 2% FBS and purified agar (OXOID) at a final concentration
of 0.7%. Cells were then incubated for 3 days at 37°C. Cells were fixed overnight with 10%
formaldehyde for the inactivation of potential  SARS-CoV-2 virus. Overlay was removed and
cells were washed once with PBS. A 2% crystal violet solution was used for plaque visualization
and count. Experiments were performed under BSL3 conditions.
Viral SARS-CoV-2 RNA Detection in Intestinal Biopsy Tissue
To detect SARS-CoV-2 RNA from intestinal biopsies, a modified version of the CDC 2019-
nCoV  real-time  RT-qPCR  was  used.  Primers  and  probes  were  commercially  available
(Integrated DNA Technologies, cat. 10006713, RUO Kit). SARS-CoV-2 primer and probe sets
consisted of two 2019-nCoV-specific sets (N1, N2). A third primer set was used to detect host
cellular RNaseP. Reactions were run using the QuantiFast Pathogen RT-PCR +IC Kit (QIAGEN,
cat. 211454). Assays were run using USA/WA-1/2020 SARS-CoV-2 RNA as a positive control
and nuclease-free water as a non-template control in a 384-well format. A plasmid containing the
genome sequence of the N protein (Integrated DNA Technologies, cat. 10006625, RUO Kit) was
used to calculate genome copy number of from their respective CT (cycle threshold) using the
linear equation from the respective plasmid standard curve. Limit of detection was established as
1-10  copies  per  µL.  Reactions  were  performed  in  duplicate  using  the  following  cycling
conditions  on  the  Roche  LightCycler  480  Instrument  II  (Roche  Molecular  Systems,
05015243001): 50°C for 20 min, 95°C for 1 sec, 95°C for 5 min, followed by 45 cycles of 95°C
for 15 sec and 60°C for 45 sec. Limit of detection for SARS-CoV-2 was determined by using a
commercially available plasmid control (Integrated DNA Technologies, cat. 10006625). 
 
Biopsy collection and processing for Mass cytometry (CyTOF)
Biopsies  were  transferred  to  10  ml  of  ‘dissociation  buffer’  (1M  HEPES(Lonza),  5M
EDTA(Invitrogen), 10% FBS in HBSS buffer (Gibco)). The tubes were kept in a shaker (180
rpm, 37C) for 20 min and then gently vortexed. Cell suspensions were collected after passing
the biopsies through 100m cell strainers. A second round of EDTA dissociation was performed
as  detailed  above.  The  cell  suspension  was  centrifuged  at  1800 rpm to  pellet  the  epithelial
fraction  and  kept  on  ice.  The  remaining  tissue  was  transferred  to  fresh  tubes  containing  a
‘digestion buffer’ (2% FBS, 0.005g Collagenase type IV per sample (Sigma), 100 l DNAse-I
(Sigma) in RPMI). Tubes were placed in the shaker (180 rpm, 37C) for 40 min and thereafter
gently vortexed. The digested tissues were filtered through 100  m cell strainers followed by
another round of filtration through 40m cell  strainers.  Cell  suspensions were centrifuged at
1800 rpm to  obtain  lamina  propria  mononuclear  cells.  Both  epithelial  cell  (EC) and lamina
propria (LP) pellets were then resuspended into 500 l of RPMI (Gibco) containing 10% FBS+
1l Rh103 +1l IdU and incubated at 37C for 20 min. 5 ml RPMI (+10%FBS) was added to
each tube and spun at 1800 rpm to pellet cells. 700 l of Prot1 stabilizer (SmartTube Inc.) was
added to each tube and transferred to cryovials and incubated at room temperature for 10 min.
Cryovials  were  immediately  transferred  to  -80C  until  the  sample  was  acquired  for  mass
cytometry as detailed below.
Blood collection and processing for CyTOF
Briefly, 15ml of Lymphosep - Lymphocyte Separation Medium (MP Bio.) was added to each
50 ml centrifugation tube. Blood was diluted with PBS to bring the volume up to 30ml and
diluted blood was layered gently over Lymphosep. Tubes were then centrifuged at 2000 rpm
 
for 20 mins with the brakes and acceleration off. After centrifugation, the buffy coat containing
PBMCs was transferred to another tube and was centrifuged at  1800 rpm to pellet  the cells.
Pellets were resuspended in PBS and tubes were centrifuged at 1800 rpm. Finally, the pellets
were resuspended in the freezing medium (10% DMSO + 44% FBS in RPMI) and cryopreserved
at -80 °C.
CyTOF processing and data acquisition 
Cells were processed as previously described by Geanon et al13. Briefly, EC and LP SmartTube
proteomic stabilized samples were thawed in a 10°C water bath and washed with Cell Staining
Buffer (Fluidigm). To facilitate data acquisition and doublet removal, multiple samples were also
barcoded using Fluidigm Pd barcoding kits and then washed and pooled for data acquisition.
Immediately prior to data acquisition, samples were washed with Cell Staining Buffer and Cell
Acquisition Solution (Fluidigm) and resuspended at a concentration of 1 million cells per ml in
Cell Acquisition Solution containing a 1:20 dilution of EQ Normalization beads (Fluidigm). The
samples were then acquired on a Helios Mass Cytometer equipped with a wide-bore sample
injector at an event rate of <400 events per second. After acquisition, repeat acquisitions of the
same sample concatenated and normalized using the Fluidigm software, and barcoded samples
were de-multiplexed using the Zunder single cell debarcoder.
CyTOF Data analysis 
De-barcoded files were uploaded to Cytobank for analyses. Immune cells were identified based
on Ir-193 DNA intensity and CD45 expression; Ce140+ normalization beads, CD45-low/Ir-193-
low debris and cross-sample and Gaussian ion-cloud multiplets were excluded from subsequent
 
downstream analysis. CyTOF antibody panel is detailed in Supplementary Data File 1. Major
immune  cell  types  were  identified  using  automated  Astrolabe  approach,  the  result  of  which
largely correlated well with our manual gating approaches. The impact of each tested condition
on relative staining quality was evaluated in two ways: 1) overall correlations were determined
by calculating the Pearson’s correlation coefficients for the median expression of each marker
across  each  defined  immune  subset;  and  2)  a  staining  index  was  calculated  using  defined
populations showing the highest and lowest expression levels of each marker: SI = (Medianpos -
Medianneg)  /  2  X  Std.Devneg.  It  is  already  been  described  that  SmartTube-based  fixation
protocols  take  into  account  previously  described  mass  cytometry  artifacts  such  as  cell-cell
multiplets, isotopic spillover or oxidation, or mass cytometer instrument configuration13. 
Statistical Analysis for CyTOF
Pre-gated viable CD45+ cells were first clustered and annotated using the Astrolabe Cytometry
Platform  (Astrolabe  Diagnostics,  Inc.),  which  involves  using  a  hierarchy-based  FlowSOM
algorithm for labeling cell populations in individual samples. These Astrolabe Profiling clusters
from each tissue type were then meta-clustered across all samples utilizing Clustergrammer2's
interactive  heatmap as  a  method  to  interrogate  antibody  expression  across  every  cluster  and
curate and assign cell population categories. Single sample clusters were also visualized using
UMAP.  Pairwise  comparisons were  performed  on  the  frequencies  of  each  identified  cell
population between the patient cohorts (COVID-19 vs. control, COVID-19 severe vs. control,
COVID19-asymptomatic/mild/moderate  vs.  control)  to  determine  fold  change,  p-values  and




Library preparation and sequencing
Directional RNA-seq libraries were prepared from 50 ng of total RNA from EC and LP samples
with the TruSeq® Stranded Total RNA prep with Ribo-Zero kit (Cat no. 20020599). Paired-end
(100 bp) sequencing was performed for DNA libraries on an Illumina NovaSeq instrument on a
NovaSeq S1 Flowcell, with an average yield of 39 million PE reads/sample.
 
RNA-seq analysis
Base-calling and quality scoring of sequencing data were done through Illumina’s Real-Time
Analysis  (RTA) software.  RNA-seq data  processing  and reference  mapping were  done with
custom  analysis  scripts  combining  publicly  available  tools  as  previously  described15 with
modifications as follows, reads were mapped to a custom reference that combined the human
hg38  reference  genome  (Release  34,  GRCh38.p13)  and  the  SARS-CoV-2  genome  (RefSeq
NC_045512) for simultaneous quantification of host and virus transcripts. 
Differential gene expression (DGE) analysis was performed with the Bioconductor edgeR
package16 using as input a combined matrix of mapped paired-end read raw counts, with genes in
rows and samples in columns.  Prior to DGE analysis, gene counts were converted to fragments
per kb per million reads (FPKM) with the RSEM package with default settings in strand-specific
mode17.
Genes  with  less  than  1  FPKM  in  at  least  50% of  the  samples  were  removed.  The
remaining gene counts were then normalized across samples using the weighted trimmed mean
of  M-values  (TMM) method18.  The  dispersion  was  estimated  by fitting  a  generalized  linear
 
model (GLM) as implemented in edgeR, sex was fitted as a covariate on a per-patient paired
design.  Pairwise  comparisons  were  performed  between  sample  groups  (i.e.,  between  tissue
sections, and between cases and controls). Significant expression differences were selected based
on eBayes adjusted p values corrected for multiple testing using the Benjamini-Hochberg method
(q ≤ 0.05).
Gene Ontology and Pathway Enrichment Analysis
KEGG pathway and gene ontology (GO) biological process (BP), molecular function (MF), and/
or cellular component (CC) enrichment analyses were performed using the gProfileR R v0.6.8
package19. The background gene set was restricted genes with detected expression (defined as
genes with expression levels above 1 FPKM in at least 50% of samples). Genes with differential
expression were ranked by log 2 fold change and used as  an ordered query.  P values  were
corrected using the g:SCS algorithm to account for multiple comparisons. 
Cell-type deconvolution and gene signature enrichment analysis
For cell-type deconvolution of the bulk RNA-seq data, Gene Set Enrichment Analysis (GSEA)
of differentially expressed genes of cases vs controls comparisons was performed against cell
type  gene-expression  single-cell  signatures  from  intestinal  mucosa20 and  gene-expression
signatures  from ileal  dendritic  cell  (DCs) subsets21.  Similarly,  differentially  expressed genes
were  tested  for  enrichment  of  gene  signatures  associated  with  an  antiviral  response,
inflammation, and cytokine signaling in acutely infected post-mortem tissue with SARS-CoV-222
, were tested for significant (p ≤ 0.05) enrichment using Fisher’s exact tests and using Bonferroni
correction for multiple comparisons. 
 
Additionally, GSEA23 was carried out on a rank ordered list of the infected EC versus
control  molecular  analysis.  The ranking metric  used was logFC * -logP value,  however,  the
results were similar when logFC metric  was also used (data not shown). For the COVID-19
associated  datasets,  we curated  two signatures  from infected  organoids24:  hSIOs-COVID-19:
human small intestinal organoids (hSIOs) grown in either i) Wnt high expansion (EXP) medium
(at adjP<0.05) or ii) differentiation (DIF) medium (at adjP<0.1). The standard GSEA settings
were  used,  namely  ‘meandiv’  for  normalization  mode,  ‘weighted’  enrichment  statistic,  and
‘1000’ permutations. GSEA using the Hallmark database (v7.125) was also performed with the
same settings. 
Computational analyses
Multivariate model based on Discovery Cohort
For this analysis, we considered 570 patients with clinical descriptors including as age, gender,
race/ethnicity,  BMI,  comorbidities  (including  hypertension,  diabetes,  chronic  lung  disease
(including asthma and COPD), heart disease (including coronary artery disease, atrial fibrillation
and heart failure), and GI symptoms. A multivariate logistic regression was utilized to model
severity and mortality as function of each of the GI symptoms and clinical variables including
race, age, gender, BMI, heart and lung diseases and hypertension.
In  particular,  race  was  stratified  as  White  (Caucasian),  Black  (African-American),
Hispanic and others; lung disease was set equal to 1 if the patient was either affected by COPD
or asthma and zero otherwise; heart disease was set equal to 1 if the patient was either affected
by  coronary  artery  disease,  atrial  fibrillation  or  heart  failure  and  0  otherwise.  The  severity
indicator was set equal to 1 for severe and severe with EOD patients and 0 for mild and moderate
COVID-19 patients; mortality was set equal to 1 for deceased patients and 0 otherwise. 
 
Significant association were determined based on 95% confidence interval (CI) based on
1000 bootstrap iterations. At each bootstrap iteration, patients were sampled with replacements
and logistic regressions were estimated considering as outcome severity and mortality.  Then,
95% CI of coefficients and odds ratio were estimated across bootstrap iterations.
External Validation Cohort
For this  analysis,  we considered  228 patients  with clinical  data  such as  age,  gender  and GI
symptoms as described in Aghemo et al1. A multivariate logistic regression was utilized to model
mortality, ICU admission and the composite outcome of ICU admission or mortality as function
of  presence  or  absence  of  diarrhea  and clinical  variables  including  age,  gender,  BMI,  heart
disease, COPD, diabetes and hypertension. Heart disease was set equal to 1 if the patient was
either affected by coronary artery disease or atrial fibrillation and 0 otherwise. CI of odds ratio
were computed based on 1000 bootstrap iterations as above.
In  270  patients  from  this  cohort  treatment  data  was  available.  Treatments  included
hydroxychloroquine, antiviral treatments including lopinavir-ritonavir and darunavir-cobicistat,
tocilizumab,  steroids,  antibiotics  including  ceftriaxone,  azithromycin,  piperacillin-tazobactam,
statins,  angiotensin-converting-enzyme (ACE) inhibitors  and angiotensin  II  receptor  blockers
(ARBs). Using this data, we performed fisher’s exact test to determine whether any treatments
were associated with diarrhea. Additionally, we computed 95% CI of odds ratio based on 1000
bootstrap iterations. 
Predictive performance based on the Internal Validation Cohort
 
For this  analysis,  we considered 233 patients  with clinical  data  including age,  BMI, and GI
symptoms. In order to evaluate the predictive performance of each model, bootstrapping was
performed.  Specifically,  at  each  bootstrap  iteration,  we  randomly  sampled  patients  in  the
Discovery Cohort with replacement and estimated a logistic regression to model each outcome as
function of a particular GI symptom, age and BMI. In this analysis, only age and BMI were
adjusted  for  since  they  were  the  only  variables  significantly  associated  with  both  outcomes
across different GI symptoms models in the Discovery Cohort (Figure 5B, Supplementary Table
9). Then, the estimated model was utilized to predict  the outcome of patients in the Internal
Validation Cohort. This procedure was repeated for 1000 bootstrap iterations. For each iteration,
Receiving  Operating  Characteristic  (ROC)  curve  and  area  under  the  curve  (AUC)  were
computed. For comparison purposes, the distribution of AUC across 1000 bootstrap iterations
from the predictive model based on age and BMI only was considered. Figure 5D shows the
boxplot of AUC values across 1000 bootstrap iterations. Then, considering the following model  
outcome =  f(age + bmi + any GI symptom) [Model 1]
we evaluated the effect of each variable on the outcome by computing the reduction in AUC
obtained after removing one variable at a time. For this purpose, the AUC of model [Model 1]
was compared to the following three models
outcome = f(age + bmi)  [Model 2]
outcome = f(age + any GI symptom)[Model 3]
outcome = f(bmi + any GI symptom)[Model 4]
for 1000 bootstrap iterations. Following the strategy above, at each bootstrap iteration, patients
were sampled with replacement. Figure 5E shows the 95% confidence intervals of difference in
AUC  between  [Model  1]  and  [Model  2],  [Model  3]  and  [Model  4]  (i.e.,  AUCModel1  -
 
AUCModel2, AUCModel1 - AUCModel3, AUCModel1 - AUCModel4) across 1000 bootstrap
iterations. The difference in AUC was computed considering both mortality and severity as the
outcome.
Average treatment effect (ATE)
The average treatment effect (ATE) for the Mount Sinai Cohort (MSH) combining Discovery
and Internal  Validation  Cohorts  and the  External  Validation  Cohort  were  calculated  via  the
TMLE package in R26. For the MSH cohort, ATE was calculated for each GI symptom using as
outcomes disease severity and mortality. The marginal effect was calculated after adjusting for
covariates such as age, race, BMI, gender, diabetes, lung disease, heart disease and hypertension.
For  the  External  Validation  Cohort,  ATE  was  calculated  for  diarrhea  on  ICU  admission,
mortality and the composite of ICU admission and mortality. The marginal effect was calculated
after adjusting for covariates such as age, BMI, gender, diabetes, lung disease, heart disease and
hypertension.
Quantification of SARS-CoV-2 nasopharyngeal viral loads
SARS-CoV-2 viral loads were determined as detailed in Pujadas et al27. Briefly, viral RNA was
extracted from the NP swab specimen followed by real time RT-PCR using N2 primers. Only
specimens with N2Cpt < 38 were included. SARS-CoV-2 viral RNA was calculated with the delta
CT  method  and  a  standard  curve.  Viral  loads  are  presented  as  log  base  10  transformed
uncorrected N2 value + 1000 (constant added before transformation)27. For patients with multiple
NP swabs available, the first swab was used for analysis.
ELLA Cytokine panel
 
The ELLA platform is a method for rapid cytokine measurement  using microfluidics ELISA
assays. The assay measured TNF-α, IL-6, IL-8, and IL-1β, previously validated by the Mount
Sinai Human Immune Monitoring Center (HIMC) using plasma from multiple myeloma patients
and recently reported for large cohort of COVID-19 patients admitted to MSH. 
Multiplexed proteomic assay (Olink)
For  analysis  of  circulating  cytokines,  we  used  a  multiplexed  proteomic  inflammation  panel
(Olink), which consists of 92 inflammation-related proteins quantified by an antibody-mediated
proximity extension-based assay. Samples with normalized protein expression values below the
limit-of-detection in >75% of samples were excluded from further analysis. For the remainder of
analytes, any sample under the limit of detection was assigned a value of the limit-of-detection
divided by the square root of 2. The log2 fold-change over the median healthy control protein
expression was then calculated,  and the  Benjamini-Hochberg procedure was used to adjust P
values for multiple testing.
Consensus Clustering of Olink Data
For  this  analysis,  we  considered  238  samples  with  GI  symptoms  annotation.  Consensus
clustering  was  performed  based  on  the  abundance  of  92  cytokines  across  all  238  samples.
Consensus clustering was performed using the R packages ConsensusClusterPlus based on z-
score normalized data. Specifically, markers were partitioned into six clusters using the K-means
algorithm, which was repeated 1000 times. Then, markers in each cluster were considered in
order to derive cluster z-score signatures via package GSVA. Based on these signatures, the
association between different clusters and GI symptoms were derived via logistic regression with
 
outcome corresponding to each GI symptom. Figure 6C shows the signed FDR (-log10 scale). P-
values were adjusted via Benjamini-Hochberg. The pathway analysis for the clusters described
above was carried out considering the entire KEGG and HALLMARK databases.
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Supplementary Figures and Tables
Supplementary Figure 1. Sample allocation for different assays in COVID-19 patients and
controls. Venn diagrams showing blood and biopsy samples used for mass cytometry (#) and
RNA sequencing (Δ) in COVID-19 patients (red) and controls (blue). The numbers in the Venn
diagrams refer to respective patient and control cases detailed Supplementary Table 2. The table









Supplementary  Figure  2.  Representative  H&E  staining  of  small  intestinal  biopsies  of
COVID-19 patients. Patient number in the top left corner corresponds with the patient number
in Supplementary Table 2. All biopsies are duodenal with the exception of patient 12 which is
from the terminal ileum. Scale bar; 100µm. 
Supplementary  Figure 3.  Intraepithelial  lymphocytes  (IELs) are  not  increased in small
intestinal biopsies from COVID-19 patients compared to controls.  (A) CD3+ and CD8+
IELs per mm of epithelium in COVID-19 patients and uninfected controls in the duodenum
(black) and ileum (gray). P-values generated from unpaired t-tests. (B) Representative IF images
of small intestinal biopsies showing CD3 (green), CD8 (red) and DAPI (blue). Representative
CD8+ IELs (arrow head) and representative CD8- IELs (arrow) are indicated. Scale bar; 100m.
Supplementary  Figure  4.  Representative  immunofluorescence  (IF)  images  of  small
intestinal biopsies of COVID-19 patients. SARS-CoV-2 nucleocapsid (green), EPCAM (red)
and DAPI (blue) in all COVID-19 patients where tissue was available for IF. Patient number in
the top right corner corresponds with the patient number in Supplementary Table 2. All biopsies
are duodenal with the exception of patient 12 which is from the terminal ileum. Patient 8 missing









SARS-CoV-2 nucleocapsid EPCAM DAPI
Supplementary Figure 5.  Representative  immunofluorescence  images of  small  intestinal
biopsies  of  control  patients.  SARS-CoV-2  nucleocapsid  (green),  EPCAM  (red)  and  DAPI
(blue) in duodenal biopsies (upper) and ileal biopsies (lower). Scale bar; 100 µm.
Supplementary Figure 6. Electron microscopy by high pressure freezing/freeze substitution
fixation  (HPF/FSF)  of  presumptive  SARS-CoV-2  infection  in  culture  Vero  cells.  (A)
Montaged  overview  of  an  infected  cell  (150  nm  section)  (presented  for  comparison  with
analogous structures  found in tissue samples  (Figure 2 and Supplementary  Movie 1),  which
could not be preserved under similar optimal conditions for EM). The cell exhibits large numbers
of  cytoplasmic  vacuoles,  surface  blebbing  and  general  cytopathogenicity.  (B)  Montaged
tomographic  reconstruction of the central  portion of the cell  shown in  A.  Large numbers of
presumptive  SARS-CoV-2 virions  are  contained  within  cytoplasmic  compartments,  most  are
closely  adjacent  to  the compartment’s  peripheries.  (C)  Gallery  of 30 individual  presumptive
SARS-CoV-2 virions taken from the tomogram shown in  B. Each example is displayed as an
equatorial view with a tomographic thickness of 4.7 nm.
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Ig M +  P la s m a  C e ll s
Supplementary Figure 7. Altered immune populations in the lamina propria of COVID-19
patients compared to controls.  (A)  Relative frequencies  of lamina propria immune cells  in
controls  and  COVID-19  patients.  Open  red  circles  denote  patients  with
asymptomatic/mild/moderate disease while filled red circles denote patients with severe COVID-
19. The bar plots show median frequencies. (B) The stacked bar graphs show the distribution of
average frequencies of naïve and memory CD4+ and CD8+ T cells in the lamina propria of
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Supplementary Figure 8. Altered immune populations in the epithelial compartment (EC)
of  COVID-19  patients  compared  to  controls.  (A) The  heat  map  shows  clustering  and
distribution  of  different  cell  types  in  the  EC.  Relative  frequencies  of  (B)  intraepithelial
lymphocytes (IELs) and (C) plasma cells in the EC of controls and COVID-19 patients. Open
red  circles  denote  patients  with  asymptomatic/mild/moderate  disease  while  filled  red  circles
denote patients with severe COVID-19. The bar plots show median frequencies.
Supplementary Figure 9. Altered immune populations in the blood of COVID-19 patients
compared to controls. (A) The heat map shows clustering and distribution of different immune
cell  types  in  the blood.  Relative  frequencies  of  (B)  classical  (dotted  bars)  and non-classical
monocytes (open bars), (C) CD4+ regulatory T cells and (D) IgG+ plasma cells in the blood of
controls  and  COVID-19  patients.  Open  red  circles  denote  patients  with
asymptomatic/mild/moderate disease while filled red circles denote patients with severe COVID-
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Supplementary Figure 10.  Altered T cell  populations in blood and intestinal biopsies of
COVID-19  patients  compared  to  controls  based  on  supervised  analysis. Representative
CyTOF plots and bar plots  comparing the frequencies  of CD29+ CD38+ CD4+ and CD29+
CD38+ CD8+ T cells in (A) the blood and (B) lamina propria of controls (blue) and COVID-19
patients (red). Open red circles denote patients with asymptomatic/mild/moderate disease while
filled red circles denote patients with severe COVID-19. The bar plots show median frequencies.
-
Supplementary  Figure  11.  Distinct  expression  profiles  in  the  intestinal  epithelial
compartment (EC) and lamina propria (LP). (A) Principal Component Analysis (PCA) of EC
and LP fractions of COVID-19 patients and controls. The two tissue fractions separate on the
principal component 1 (x-axis).  (B) Hierarchical clustering of average expression changes for
6636  genes  (rows)  characterizing  the  EC (red)  or  LP  (blue)  fractions  (FDR ≤  0.05)  in  the
intestinal biopsies of COVID-19 patients and controls. The left panel indicates significant genes
in yellow for each tissue compartment. The color bar (right panel) indicates the average log2
fold-change (FC).
Supplementary  Figure  12.  Immune  signatures  in  the  epithelial  compartment  (EC)  of
COVID-19  patients.  Gene  Set  Enrichment  Analysis  (GSEA)  was  performed  using  a  rank
ordered list of genes differentially expressed in the infected EC vs control EC. The metric for
ranking was logFC*-logPvalue. (A) GSEA was performed on the rank ordered EC gene set using
SARS-CoV-2 infected organoid datasets. The gene sets tested were molecular signatures curated
from  SARS-CoV-2  infected  organoid  experimental  datasets  using  human  small  intestinal
organoids (hSIOs) grown in either i) Wnt high expansion (EXP) medium (at adjP < .05) or ii)
differentiation  (DIF) medium (at  adjP  < .1).   Only gene sets  significantly  enriched (at  FDR
<0.05) are displayed. (B) GSEA was performed for the same rank ordered EC gene set using the
Hallmark Pathway datasets. Two significantly enriched pathways were found to be associated
with  upregulated  genes  in  infected  EC  relative  to  controls  (at  FDR<0.05).  Normalized
enrichment score (NES) and FDR values are as indicated.  
Supplementary Figure 13.  Flow diagram of the Discovery Cohort. The diagram shows the
total number of patients admitted to the Mount Sinai Health System between April 1-15, 2020
and the selection process that was adopted in order to select patients in the Discovery Cohort. 
Supplementary Figure 14.  Nausea and vomiting were associated with reduced mortality
and severity. Kaplan-Meier curves for mortality stratified by (A) nausea and (B) vomiting for
patients in the Discovery Cohort.  P-values from log-rank test and 95% confidence intervals of
Kaplan-Meier curves are shown. Below each Kaplan-Meier, the number of patients at risk for
different time points are reported. 
Supplementary Figure 15.  COVID-19 patients with GI symptoms had reduced levels of
circulating  IL-6  and  IL-8.  (A) IL-6,  (B) IL-8,  (C) TNF-α  and  (D) IL-1β  at  the  time  of
admission  in  patients  with  and  without  GI  symptoms.  Boxplots  represent  the  median  and
interquartile range. P-values calculated using unpaired two-tailed t-test.
Supplementary Figure 16. Correlation matrix (Pearson’s) for 92 markers contained in the
Olink platform.  (A) Correlation matrix across patients with nausea (left  panel) compared to
patients without nausea (right panel); and  (B) patients with vomiting (left panel) compared to
patients  without  vomiting  (right  panel).  Cluster  assignment  derived  using  unsupervised
consensus clustering is reported on the top of the heatmap.
Supplementary Table 1. Biopsy cohort characteristics
 Characteristic
COVID-19 biopsy 




 Age (mean years ± stdev*) 54 ± 20 65 ± 11 0.12
 Male sex 12 (63%) 5 (50%) 0.69
 Number of comorbidities §                                                                                                                                
  (mean ± stdev*)
 Hospitalized patients 12 (63%) 6 (60%) >0.99
 COVID-19 characteristics
 Asymptomatic / mild / moderate COVID-19 12 (63%) NA NA
 Severe COVID-19 7 (37%) NA NA
 COVID-19 associated GI symptoms ^ 3 (16%) NA NA
* stdev = standard deviation
^ = GI symptoms defined as nausea, vomiting and /or diarrhea at the time of acute illness
§ = Hypertension (HTN), obesity (OB), diabetes mellitus (DM), asthma (A), chronic obstructive pulmonary 
disease (COPD), coronary artery disease (CAD), cancer (CX), transplant (TPX)
1.9 ± 1.6 2.0 ± 1.1 0.93
Supplementary Table 2. Individual patient characteristics from biopsy cohort. 
(included as separate excel)
Supplementary Table 3. Criteria for scoring disease severity in COVID-19 patients.
Severity Score Criteria
Mild SpO2>94% on room air AND no pneumonia on imaging
Moderate SpO2<94% on room air OR pneumonia on imaging
Severe
High  flow  nasal  cannula  (HFNC),  non-rebreather  mask  (NRBM),  Bilevel  Positive
Airway Pressure (non-invasive positive airway ventilation),  or Mechanical  ventilation
AND no pressor medications AND creatinine clearance > 30 AND ALT < 5x upper limit
of normal
Severe  with  end  organ
damage (EOD)
High  flow  nasal  cannula  (HFNC),  non-rebreather  mask  (NRBM),  Bilevel  Positive
Airway Pressure (non-invasive positive airway ventilation),  or Mechanical  ventilation
AND  pressor  medications  OR  creatinine  clearance  <30  OR  new  renal  replacement
therapy OR ALT > 5x upper limit of normal
Supplementary Table 4. Histopathological characteristics of COVID-19 patients.
Supplementary Table 5. Histopathological characteristics of pre-pandemic controls.

Supplementary Table 6. Discovery Cohort basic demographics, clinical characteristics and
outcomes. For age, the mean ± standard deviation is listed. For categorical variables, the
number of patients followed by the percent of patients in parentheses is listed. 
Discovery Cohort (n=634)










Diabetes mellitus 141 (22.2)
Obesity (BMI>30)* 211 (37.1)
Chronic lung disease 59 (9.3)
Heart disease 111 (17.5)








Severe with EOD 61 (9.6)
Outcomes






Any GI symptoms 299 (47.2)
*BMI information available on 568/634 patients
Supplementary Table 7.  COVID-19 disease severity and mortality  in patients  with and
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Supplementary  Table  8.  Basic  demographics  in  survivors  and  non-survivors  in  the
Discovery Cohort. For age, the mean ± standard deviation and an unpaired two-tailed t-
test  was  performed.  For  categorical  variables,  the  number  of  patients  followed  by the
percent of patients in parentheses is listed and the Fisher’s exact test or the Chi-square test





Age (years) 61.3 ± 15.2 72.6 ± 14.1 <0.0001
Male 287 (59.4) 82 (54.3) 0.30
Disease severity
Mild 48 (9.9) 6 (4.0)  
Moderate 318 (65.8) 43 (28.5)  
Severe 95 (19.7) 63 (41.7)  
Severe with EOD 22 (4.6) 39 (25.8) <0.0001
Supplementary  Table  9.  Confidence  intervals  of  odds  ratio  based  on  1000  bootstrap
iterations for severity, mortality and ICU admission in the Discovery Cohort.
Severity 2.5% 50% 97.5%
(Intercept) 0.015 0.071 0.320
Any GI Symptom 0.378 0.559 0.844
baseline.GenderMale 0.939 1.380 2.090
baseline.Age 1.004 1.016 1.031
baseline.DIABETES 0.600 0.995 1.729
baseline.BMI 1.009 1.039 1.069
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.293 0.503 0.876
baseline.RACE_ETHNICITY_HISPANIC 0.688 1.188 2.035
baseline.RACE_ETHNICITY_OTHER 0.771 1.286 2.245
baseline.HTN 0.636 0.990 1.543
baseline.Lung.Disease 0.272 0.562 1.063
baseline.Heart.Disease 0.673 1.095 1.842
2.5% 50% 97.5%
(Intercept) 0.013 0.060 0.259
Diarrhea 0.433 0.653 0.978
baseline.GenderMale 0.963 1.413 2.124
baseline.Age 1.005 1.017 1.033
baseline.DIABETES 0.604 1.012 1.747
baseline.BMI 1.008 1.037 1.067
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.300 0.521 0.920
baseline.RACE_ETHNICITY_HISPANIC 0.707 1.215 2.098
baseline.RACE_ETHNICITY_OTHER 0.777 1.311 2.280
baseline.HTN 0.634 0.977 1.529
baseline.Lung.Disease 0.267 0.546 1.042
baseline.Heart.Disease 0.686 1.113 1.826
2.5% 50% 97.5%
(Intercept) 0.013 0.058 0.271
Nausea 0.329 0.563 0.880
baseline.GenderMale 0.932 1.364 2.089
baseline.Age 1.005 1.018 1.032
baseline.DIABETES 0.609 1.015 1.738
baseline.BMI 1.007 1.036 1.065
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.322 0.543 0.946
baseline.RACE_ETHNICITY_HISPANIC 0.749 1.264 2.169
baseline.RACE_ETHNICITY_OTHER 0.816 1.340 2.338
baseline.HTN 0.615 0.950 1.477
baseline.Lung.Disease 0.248 0.516 0.980
baseline.Heart.Disease 0.676 1.091 1.830
2.5% 50% 97.5%
(Intercept) 0.012 0.054 0.236
Vomiting 0.190 0.399 0.732
baseline.GenderMale 0.938 1.395 2.107
baseline.Age 1.006 1.018 1.032
baseline.DIABETES 0.615 1.032 1.744
baseline.BMI 1.006 1.036 1.065
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.330 0.558 0.962
baseline.RACE_ETHNICITY_HISPANIC 0.766 1.286 2.191
baseline.RACE_ETHNICITY_OTHER 0.802 1.337 2.307
baseline.HTN 0.610 0.950 1.511
baseline.Lung.Disease 0.261 0.526 0.981
baseline.Heart.Disease 0.703 1.123 1.886
Mortality 2.5% 50% 97.5%
(Intercept) 0.000 0.003 0.022
Any GI Symptom 0.335 0.544 0.861
baseline.GenderMale 0.679 1.049 1.703
baseline.Age 1.036 1.053 1.074
baseline.DIABETES 0.527 0.930 1.605
baseline.BMI 1.010 1.043 1.081
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.529 1.035 1.959
baseline.RACE_ETHNICITY_HISPANIC 0.867 1.597 2.899
baseline.RACE_ETHNICITY_OTHER 0.450 0.878 1.630
baseline.HTN 0.600 1.007 1.665
baseline.Lung.Disease 0.342 0.778 1.577
baseline.Heart.Disease 0.652 1.154 2.028
2.5% 50% 97.5%
(Intercept) 0.000 0.003 0.017
Diarrhea 0.388 0.638 0.985
baseline.GenderMale 0.702 1.076 1.737
baseline.Age 1.038 1.055 1.076
baseline.DIABETES 0.531 0.945 1.608
baseline.BMI 1.007 1.041 1.079
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.562 1.071 2.020
baseline.RACE_ETHNICITY_HISPANIC 0.901 1.640 2.898
baseline.RACE_ETHNICITY_OTHER 0.468 0.900 1.709
baseline.HTN 0.595 1.001 1.665
baseline.Lung.Disease 0.333 0.752 1.561
baseline.Heart.Disease 0.660 1.166 2.020
2.5% 50% 97.5%
(Intercept) 0.000 0.003 0.019
Nausea 0.255 0.490 0.886
baseline.GenderMale 0.669 1.041 1.719
baseline.Age 1.038 1.055 1.075
baseline.DIABETES 0.528 0.938 1.623
baseline.BMI 1.006 1.040 1.077
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.591 1.112 2.116
baseline.RACE_ETHNICITY_HISPANIC 0.956 1.718 3.085
baseline.RACE_ETHNICITY_OTHER 0.474 0.916 1.703
baseline.HTN 0.579 0.960 1.571
baseline.Lung.Disease 0.313 0.699 1.457
baseline.Heart.Disease 0.655 1.155 2.007
2.5% 50% 97.5%
(Intercept) 0.000 0.002 0.016
Vomiting 0.116 0.364 0.753
baseline.GenderMale 0.690 1.070 1.759
baseline.Age 1.038 1.055 1.076
baseline.DIABETES 0.558 0.970 1.652
baseline.BMI 1.006 1.040 1.077
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.609 1.145 2.144
baseline.RACE_ETHNICITY_HISPANIC 1.004 1.746 3.086
baseline.RACE_ETHNICITY_OTHER 0.463 0.907 1.697
baseline.HTN 0.586 0.974 1.620
baseline.Lung.Disease 0.318 0.717 1.489
baseline.Heart.Disease 0.670 1.186 2.025
ICU admission 2.5% 50% 97.5%
(Intercept) 0.03 0.17 1.11
Any GI Symptom 0.46 0.75 1.19
baseline.GenderMale 1.23 2.00 3.26
baseline.Age 0.98 0.99 1.01
baseline.DIABETES 0.91 1.70 3.23
baseline.BMI 0.98 1.02 1.05
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.26 0.57 1.20
baseline.RACE_ETHNICITY_HISPANIC 0.79 1.50 2.95
baseline.RACE_ETHNICITY_OTHER 0.48 0.98 1.99
baseline.HTN 0.34 0.61 1.08
baseline.Lung.Disease 0.15 0.63 1.45
baseline.Heart.Disease 0.20 0.51 0.97
2.5% 50% 97.5%
(Intercept) 0.02 0.16 1.10
Diarrhea 0.45 0.76 1.25
baseline.GenderMale 1.23 2.00 3.27
baseline.Age 0.98 0.99 1.01
baseline.DIABETES 0.89 1.70 3.25
baseline.BMI 0.98 1.02 1.05
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.26 0.56 1.19
baseline.RACE_ETHNICITY_HISPANIC 0.78 1.50 2.96
baseline.RACE_ETHNICITY_OTHER 0.48 0.98 1.98
baseline.HTN 0.34 0.61 1.09
baseline.Lung.Disease 0.15 0.62 1.44
baseline.Heart.Disease 0.20 0.52 0.99
2.5% 50% 97.5%
(Intercept) 0.02 0.14 0.95
Nausea 0.45 0.85 1.42
baseline.GenderMale 1.24 2.00 3.33
baseline.Age 0.98 0.99 1.01
baseline.DIABETES 0.91 1.74 3.31
baseline.BMI 0.98 1.02 1.05
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.27 0.60 1.25
baseline.RACE_ETHNICITY_HISPANIC 0.81 1.54 3.00
baseline.RACE_ETHNICITY_OTHER 0.49 0.99 1.97
baseline.HTN 0.33 0.59 1.06
baseline.Lung.Disease 0.14 0.60 1.40
baseline.Heart.Disease 0.20 0.51 0.98
2.5% 50% 97.5%
(Intercept) 0.02 0.15 0.98
Vomiting 0.16 0.53 1.08
baseline.GenderMale 1.21 1.98 3.26
baseline.Age 0.98 0.99 1.01
baseline.DIABETES 0.92 1.74 3.31
baseline.BMI 0.98 1.02 1.05
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN 0.27 0.60 1.26
baseline.RACE_ETHNICITY_HISPANIC 0.82 1.55 3.01
baseline.RACE_ETHNICITY_OTHER 0.48 0.99 1.96
baseline.HTN 0.34 0.61 1.07
baseline.Lung.Disease 0.15 0.62 1.43
baseline.Heart.Disease 0.20 0.52 0.99
Supplementary Table 10.  Age, gender and mortality in an External Validation (Italian)
Cohort stratified by presence or absence of diarrhea on admission. For age, the mean  ±
standard  deviation  and  an  unpaired  two  tailed  t-test  was  performed.  For  categorical
variables, the number of patients followed by the percent of patients in parentheses is listed
and the Fisher’s exact test or the Chi-square test was used as appropriate.
Diarrhea on admission
(n=80)
No diarrhea on 
admission (n=207) p-value
Age (years) 60.6 ± 13.9 65.5 ± 13.3 0.006
Male 46 (57.5) 149 (72.0) 0.024
ICU admission 9 (11.3) 43 (20.8) 0.06
Mortality 8 (10.0) 49 (23.7) 0.008
Death or ICU admission 16 (20.0) 83 (40.1) 0.001
Supplementary  Table  11.  Association  between  diarrhea  and  treatment  in  External
Validation Cohort  using Fisher’s exact  test.  Association between diarrhea and outcome
after adjusting for treatment based on External Validation Cohort. Quantile of odds ratio















Outcome: Death 2.50% 50% 97.50%
(Intercept) 0.025 0.138 0.434
diarrhea 0.111 0.313 0.699
treatment.Hydroxychloroquine 0.170 0.706 2.965
treatment.Lopinavir.ritonavir 0.740 2.397 11.006
treatment.Darunavir.cobicistat 0.477 1.723 8.455
treatment.Tocilizumab 0.000 0.472 2.692
treatment.Steroids 0.000 1.626 7.849
treatment.Ceftrixone 0.415 1.079 3.740
treatment.Azithromicin 0.252 0.651 1.462
treatment.Piperacillin.Tazobactam 0.961 3.014 11.740
treatment.Statins 0.981 2.261 5.127
treatment.ACE.inhibitors 0.588 1.503 3.413
treatment.ARBs 0.502 1.389 3.645
 
Outcome: ICU 2.50% 50% 97.50%
(Intercept) 8.89E-10 1.15E-08 3.40E-08
diarrhea 0.122 0.407 1.083
treatment.Hydroxychloroquine 1.52E-09 0.093814 1.265738
treatment.Lopinavir.ritonavir 33992289 318000000 4.11E+16
treatment.Darunavir.cobicistat 9669004 96256078 1.13E+16
treatment.Tocilizumab 3.17E-08 1.93167 11.84107
treatment.Steroids 0.557 4.866 46.290
treatment.Ceftrixone 0.474 1.606 8.810
treatment.Azithromicin 0.264 0.719 1.756
treatment.Piperacillin.Tazobactam 0.097 0.807 6.591
treatment.Statins 0.140 0.580 1.655
treatment.ACE.inhibitors 0.192 0.683 2.022
treatment.ARBs 0.381 1.362 3.893
 
Outcome: ICU or Death 2.50% 50% 97.50%
(Intercept) 0.054 0.219 0.674
diarrhea 0.126 0.297 0.585
treatment.Hydroxychloroquine 0.000 0.144 0.729
treatment.Lopinavir.ritonavir 4.142 22.183 215000000
treatment.Darunavir.cobicistat 2.143 11.491 102000000
treatment.Tocilizumab 0.000 1.198 7.012
treatment.Steroids 1.424 8.464 75358718
treatment.Ceftrixone 0.559 1.304 4.167
treatment.Azithromicin 0.224 0.510 1.003
treatment.Piperacillin.Tazobactam 0.656 2.090 7.553
treatment.Statins 0.696 1.595 3.529
treatment.ACE.inhibitors 0.615 1.409 2.987
treatment.ARBs 0.668 1.642 4.449
Supplementary Table 12.  Confidence interval of AUC (95%) based on 1000 bootstrap
iterations for severity, mortality and ICU admission in the Internal Validation Cohort.
Severity 2.50% 50% 97.50%
Age + BMI 0.539 0.587 0.598
Age + BMI + Nausea 0.567 0.608 0.619
Age + BMI + Vomiting 0.558 0.607 0.618
Age + BMI + Diarrhea 0.574 0.630 0.651
Age + BMI + Any GI symptoms 0.605 0.640 0.651
Mortality 2.50% 50% 97.50%
Age + BMI 0.685 0.700 0.702
Age + BMI + Nausea 0.698 0.717 0.722
Age + BMI + Vomiting 0.702 0.719 0.724
Age + BMI + Diarrhea 0.697 0.718 0.726
Age + BMI + Any GI symptoms 0.708 0.727 0.736
ICU admission 2.50% 50% 97.50%
Age + BMI 0.534 0.560 0.599
Age + BMI + Nausea 0.496 0.523 0.650
Age + BMI + Vomiting 0.488 0.515 0.626
Age + BMI + Diarrhea 0.562 0.649 0.667
Age + BMI + Any GI symptoms 0.570 0.647 0.670
Supplementary Table 13.  IL-6,  IL-8,  TNF-α, and IL-1β concentrations on admission in
patients with and without GI symptoms. Benjamini adjusted p-values (signed - log10 scale)
from t-test are reported. Association passing a 10% FDR are highlighted in yellow.
Nausea Vomiting Diarrhea Any GI Symptoms
IL-6 -1.958 -0.473 -2.226 -2.484
IL-8 -4.098 -1.440 -2.302 -3.133
TNF-α -0.815 -0.311 -0.406 -0.864
IL-1β -0.295 -0.473 -0.295 -0.295
Supplementary Table 14. Cluster assignment for each of the 92 Olink analytes.
Marker Cluster Marker Cluster
IL8 1 MCP.3 4
AXIN1 1 OPG 4
OSM 1 uPA 4
CCL4 1 IL6 4
TGF.alpha 1 MCP.1 4
TNFSF14 1 IL18 4
HGF 1 IL.18R1 4
SIRT2 1 IL10 4
EN.RAGE 1 CCL23 4
CASP.8 1 CXCL10 4
TWEAK 1 LIF 4
STAMBP 1 CCL20 4
VEGFA 2 ADA 4
CDCP1 2 GDNF 5
IL.17C 2 IL.17A 5
CXCL9 2 IL.20RA 5
CST5 2 IL.2RB 5
FGF.23 2 IL.1.alpha 5
FGF.5 2 IL2 5
LIF.R 2 TSLP 5
FGF.21 2 SLAMF1 5
IL.15RA 2 IL.10RA 5
IL.10RB 2 IL.22.RA1 5
PD.L1 2 Beta.NGF 5
MMP.10 2 IL.24 5
TNF 2 IL13 5
CD5 2 ARTN 5
X4E.BP1 2 IL.20 5
CD40 2 CCL28 5
CCL25 2 IL33 5
CX3CL1 2 IL4 5
TNFRSF9 2 NRTN 5
CSF.1 2 NT.3 5
CD8A 3 IL5 5
CD244 3 IL7 6
TRAIL 3 LAP.TGF.beta.1 6
CD6 3 CXCL11 6
SCF 3 CXCL1 6
CCL11 3 MCP.4 6
CCL19 3 MMP.1 6
TRANCE 3 CXCL5 6
IL.12B 3 CXCL6 6







Supplementary Table 15.  Olink analytes in patients with and without GI symptoms. P-
values from t-test comparing patients with and without GI symptoms. Signed Benjamini-
Hochberg adjusted p-value (-log10 scale) are reported.
Any GI 
Symptoms Nausea Vomiting Diarrhea
IL8 -1.315 -0.654 -1.345 -1.562
VEGFA 0.006 0.014 -0.356 -0.027
CD8A -0.823 -0.175 0.193 -0.823
MCP.3 -0.524 -1.437 -0.422 -0.254
GDNF -1.355 -1.345 -0.014 -1.490
CDCP1 -0.449 -0.309 -0.175 -0.524
CD244 -0.023 0.110 0.126 -0.017
IL7 1.345 0.175 -0.123 1.345
OPG -2.183 -1.209 -0.014 -2.183
LAP.TGF.beta.1 0.356 -0.006 -0.626 0.407
uPA -0.156 -0.009 0.126 -0.385
IL6 -1.063 -1.022 -0.254 -0.747
IL.17C -1.209 -0.287 -0.023 -1.455
MCP.1 -0.175 -0.654 -0.458 -0.187
IL.17A -2.183 -1.097 -1.419 -2.183
CXCL11 0.058 -0.195 -0.004 0.027
AXIN1 -0.009 -0.031 -1.209 -0.026
TRAIL 1.063 0.626 0.314 0.458
IL.20RA -0.548 -0.573 -0.563 -0.618
CXCL9 -0.573 -0.367 0.023 -1.209
CST5 -0.626 -0.187 -0.004 -0.969
IL.2RB -0.156 -0.028 0.009 -0.044
IL.1.alpha 0.046 -0.023 0.001 0.162
OSM -0.178 -0.117 -0.175 -0.242
IL2 -0.341 -0.424 -0.287 -0.264
CXCL1 -0.058 -0.533 -0.733 -0.164
TSLP 0.009 0.001 -0.031 -0.009
CCL4 -0.287 -0.022 0.022 -1.355
CD6 -0.001 0.027 0.363 0.001
SCF -0.245 -0.022 -0.114 -0.082
IL18 -0.254 -0.068 0.332 -0.434
SLAMF1 -0.618 -0.707 -0.190 -0.708
TGF.alpha -1.087 -0.626 -0.675 -1.345
MCP.4 0.191 -0.175 -0.461 0.058
CCL11 -0.327 -0.440 -1.209 -0.260
TNFSF14 0.014 -0.014 -0.434 -0.012
FGF.23 -0.556 -0.058 0.036 -1.209
IL.10RA 0.027 0.218 -0.044 -0.026
FGF.5 -0.823 -0.164 -0.027 -1.365
MMP.1 0.110 0.156 -0.218 0.027
LIF.R -0.347 -0.009 0.310 -0.358
FGF.21 -0.495 -0.003 0.056 -0.880
CCL19 -0.044 -0.227 -0.156 -0.175
IL.15RA -1.345 -0.175 0.022 -2.177
IL.10RB -1.355 -0.389 -0.079 -2.183
IL.22.RA1 -0.073 -0.022 -0.009 -0.254
IL.18R1 -0.208 -0.054 0.175 -0.156
PD.L1 -0.441 -0.195 0.031 -0.702
Beta.NGF -0.573 -0.458 -0.022 -0.495
CXCL5 -0.014 -0.144 -0.424 -0.042
TRANCE 0.933 0.458 0.236 0.654
HGF -0.626 -0.333 -0.009 -0.529
IL.12B 0.060 0.058 -0.009 0.038
IL.24 -0.536 -0.218 0.023 -0.618
IL13 -0.007 0.075 0.068 -0.126
ARTN -1.209 -1.365 -0.618 -1.345
MMP.10 -1.562 -0.967 -0.156 -2.073
IL10 -0.379 -0.377 0.058 -0.270
TNF -0.643 -0.175 -0.027 -0.932
CCL23 -0.023 -0.218 0.001 0.001
CD5 -0.823 -0.357 -0.036 -0.933
CCL3 -0.933 -0.553 -0.576 -1.490
Flt3L 0.031 -0.009 -0.377 -0.009
CXCL6 -0.156 -0.385 -0.347 -0.385
CXCL10 -0.001 -0.441 -0.012 0.031
X4E.BP1 -0.733 -0.211 0.064 -1.223
IL.20 -0.247 -1.022 -0.270 -0.195
SIRT2 -0.123 -0.164 -0.332 -0.162
CCL28 -2.183 -2.183 -0.737 -2.183
DNER 0.175 0.317 0.332 0.202
EN.RAGE -0.357 -0.193 -0.166 -0.526
CD40 -0.823 -0.079 0.001 -1.490
IL33 -0.236 -0.164 0.023 -0.287
IFN.gamma 0.218 0.044 0.175 0.270
FGF.19 -0.458 -0.001 -0.036 -1.355
IL4 -0.020 -0.175 -0.027 -0.009
LIF -1.345 -0.526 -0.573 -1.355
NRTN 0.001 -0.168 -0.036 -0.012
MCP.2 0.319 -0.327 -0.036 1.231
CASP.8 -0.438 -0.377 -0.264 -0.731
CCL25 -0.264 0.025 -0.075 -0.626
CX3CL1 -0.556 -0.164 -0.009 -0.810
TNFRSF9 -1.345 -0.175 -0.012 -2.029
NT.3 -0.012 -0.363 0.009 -0.122
TWEAK -0.014 0.014 -0.113 -0.012
CCL20 -0.737 -0.576 0.187 -0.823
ST1A1 0.156 -0.025 -0.175 0.068
STAMBP -0.201 -0.171 -0.175 -0.377
IL5 0.156 -0.009 0.156 -0.009
ADA -0.259 -0.270 0.175 -0.434
TNFB 0.009 -0.009 -0.036 0.014
CSF.1 -0.458 -0.028 0.012 -0.450





ACE2 Polyclonal Abcam ab15348 rabbit Unconjugated 1:1000
EPCAM SPM491 GeneTex GTX34693 mouse Unconjugated 1:100
SARS-CoV-2 
nucleocapsid
Polyclonal NA NA rabbit Unconjugated 1:2000




Abcam ab199016 mouse Unconjugated 1:200




Polyclonal Abcam ab37415 rabbit Unconjugated variable
Yeast GAL4
(isotype control) 
15-6E10A7 Abcam ab170190 mouse Unconjugated variable
Mouse IgG H&L Polyclonal Abcam ab150116 goat Alexa Fluor 594 1:1000
Rabbit IgG H&L Polyclonal Abcam ab150077 goat Alexa Fluor 488 1:1000
Supplementary Movie 1. Montaged tomographic reconstruction of Golgi region of a goblet cell
in apical epithelium of the terminal ileum of a COVID-19 patient. The movie begins with an
overview of the goblet cell Golgi complex within a reconstructed volume of a 150 nm section.
Intestinal epithelial cells border the goblet cell on the left and right side, and the apical portion of
the epithelium is in the upper right, outside of the field of view. The movie progressively zooms
in to detail a membrane-bound compartment located at the trans-side of the Golgi stack. This
compartment contains five presumptive SARS-CoV-2 virions that closely resemble the structures
illustrated  in  Supplementary  Figure  6  and  in  similar  datasets  of  presumptive  SARS-CoV-2
virions in SARS-CoV-2 infected cultured cells in Supplementary Movie 2.
Supplementary Movie 2. Tomographic reconstruction of SARS-CoV-2–infected cultured cells,
prepared  by  high-pressure  freezing  and  freeze-substitution fixation. The  movie, which  is
presented  for  comparison  with  analogous  structures  found  in  tissue  samples (Figure  2  and
Supplementary Movie 1) that could not be preserved under similar optimal conditions, shows an
overview of a central portion of an infected cell, featuring large numbers of presumptive SARS-
CoV-2 virions  within membrane-bound compartments, and then increases  in  magnification  to
show  details  of  groups  of  presumptive  virions and  then  individual  presumptive  virions
themselves. Note the consistent presence of dense nucleocapsid puncta arranged within the core
of each presumptive virion, membrane bilayers, and occasional surface spike densities visible
through the volume. 
